US Residential Fund Distribution of 1.5 cents September 2016

27th September 2016, ASX Announcement

US Residential Fund (ASX: USR) is pleased to announce a distribution of 1.5 cents per stapled security for the quarter ended 30 September 2016. This distribution equates to an annualised yield of 11.3% at teh security price at market close on 26 September 2016.

In respect of the payment of the distribution for the quarter ended 30 June 2016, USR confirms that this will be paid on 7 October 2016.

USR Managing Director Andrew Meakin said: “We continue to explore capital raising options and increase our reach in property syndication market through Global Crowd and Crowd Street.

To view the full announcement, please click on the button below.

Folkestone Maxim A-REIT Securities Fund Added to Asgard

26th September 2016

Folkestone Maxim is pleased to announce that the Folkestone Maxim A-REIT Securities Fund has been added to the Asgard platform.

Read more

About Folkestone Maxim A-REIT Securities Fund

The Folkestone Maxim A-REIT Securities Fund is a high conviction fund providing access to a diversified portfolio of quality ASX listed real estate securities which own office, retail and industrial, residential and real estate related social infrastructure assets. The Fund’s investment style follows an active management style coupled with a disciplined approach focusing on a top down/bottom-up process. Securities are selected on a concentrated portfolio basis built on individual merit and not benchmark weights.

Download PDS

SuiteBox Expands APAC Team

26th September 2016

SuiteBox, the mobile office solution for professionals, has appointed Andy Marshall to lead its APAC sales efforts.

Ian Dunbar, SuiteBox CEO, said: “I’m delighted to have Andy joining the SuiteBox team and heading up our sales efforts in Asia Pacific. Andy’s experience and insights into what advice customers really want, and how advisers can deliver experiences that drive advocacy and loyalty through the use of technology, align perfectly with SuiteBox’s mantra of enabling client engagement for professionals.”

The author of over 200 practice management articles, Mr Marshall is one of the most widely shared and read contributors to industry publications. He brings with him 28 years of experience in financial markets, academic research in the fields of psychology and neuroscience and financial advice best practice.

Andy Marshall, SuiteBox Regional Sales Manager – APAC, said: “It’s an exciting time to join an award winning innovation leader like SuiteBox.  My role is to focus the sales efforts on partnering with organisations that want to take their client relationships and services to new levels and institutions who want to equip their adviser force with leading client engagement technology. Client engagement with efficiency, meaning, relevance and ensuring compliance (the proper recording of advice via processes like file notes) has remained a challenge for advisers and any professional balancing risk management, process and engagement. At a time when client wants and their use of technology is changing, they are looking for solutions that fit with busy lifestyles.  Efficiency is key, but so is connection.  SuiteBox as a platform offers the solution to that balance.”

Andy has been involved in financial markets since 1988, he is a Senior Associate of Finsia, holds a Bachelor of Science (Melbourne University), a Diploma of Financial Markets (Securities Institute) and the Diploma of Financial Planning (Deakin). He is currently studying towards a Bachelor of Behavioural Studies– Psychology major, Advanced Psychology and Sociology minors from Swinburne University.

OncoSil Receives $2.3m R&D Tax Incentive Refund

26th September 2016, ASX Announcement

OncoSil Medical Limited (ASX:OSL) (OncoSil Medical or the Company) a late stage medical company focused on localised treatments for subjects with pancreatic and liver cancer, is pleased to announce it has received a cash refund from the Australian Taxation Office of $2.3 million following the lodgement of the 2015/16 financial year tax return. The cash is rebate is related to the expenditure on eligible Australian and international R&D activities conducted during the 2015/16 financial year.

The Company has approximately $14.0m in cash and cash equivalents with the receipt of these funds.

To view the full announcement, please click on the button below.

BPS Expands US Bartercard Operations by 50% in One Month

26th September 2016, ASX Announcement

Highlights

  • BPS continues to execute its Bartercard growth strategy in North America, opening six new franchises across the US in a record-breaking month
  • Bartercard now has a presence in eight states which represent 25% of US economic output
  • BPS is continuing to pursue a robust pipeline of potential US franchises

Leading financial technology platform provider BPS Technology Limited (ASX:BPS, “the Company”) is pleased to announce that it has continued to expand the reach of its Bartercard operations in North America.

In a record-breaking month of signings, BPS has just opened six new franchises across the US, growing the Company’s US business network to 18 franchises.

To view the full announcement, please click on the button below.

MedAdvisor features in CommSec Executive Series

21st September 2016, ASX Announcement

MedAdvisor Limited (ASX: MDR, the Company) Australia’s leading digital medication adherence company are featured in CommSec’s Executive Series.

Mr Robrt Read, CEO of MedAdvisor provides an update on the Company’s full year results, progress to date, its proposed acquisition of Healthnotes, and plans for growth in FY 2017.

A selection of  highlights from the interview are as follows:

  • Operations have increased during the FY16
    - Doubled patient numbers on the platform
    - Pharmacy market share incrased from 20% to 30%

To view the full announcement, please click on the button below.

MHOR Australian Small Cap Outperforms the Small Ordinaries Benchmark by +4.52%

Welcome to the first monthly report for the MHOR Australian Small Cap Fund.  The fund got off to a positive start in its first month, outperforming the Small Ordinaries Benchmark by +4.52%. This comprised a +2.95% absolute positive return (our focus) against a market backdrop of -1.56%.

We started the month with 100% cash and worked steadily through the month to a roughly 95% invested position across 29 listed stocks and 1 pre-IPO investment. During the month, the fund averaged around 50% invested, meaning our underlying stocks performed considerably better than the headline +2.95% absolute performance in the period.

After some positive press the fund has seen a surge in applications. Word of mouth and the inflows has timed nicely with a number of new companies identified to go into the portfolio coupled with our desire to keep a strong cash buffer into the weeks ahead of the US election.

MHOR is expanding, we are pleased to welcome Dominic Rose to the MHOR team. Until recently Dominic was the head of small cap research at Deutsche Bank. Dominic has a long history with small cap stocks and is already adding serious value to the portfolio. Welcome to MHOR Dominic.

To download the MHOR Australian Small Cap Fund August report click here.

MedAdvisor Annual Report to Shareholders 2016

23rd September 2016, ASX Announcement

Chairmans Letter

In the rapidly expanding MedAdvisor world there has been little time for reflection,; nonetheless, we critically measure our performance, our wins, and our also-rans but we rarely muse on the past. Our Annual Report forces you to do so.

Our company has completed a transformative year – from having no operating business we have plunged into the extraordinarily energized domain linking information technology with better health.

We are positioned at the convergence of rising health costs, increasingly complex medication regimes and the clear need for efficacy and patient management in individual health management.

To view the full announcement, please click on the button below.

SUDA Annual Report to Shareholders 2016

22nd September 2016, ASX Announcement

Letter From The Chairman 

“Our global reputation in oro-mucosal drug delivery is growing as we continue to generate new discussion with potential partners as well as progressing existing discussions along the project cycle.”

Looking at the share price over the last 15 months suggests that the 2015-16 year was not a good year for SUDA, or for our shareholders. We continue to be very conscious of our shareholders’ expectations and anticipation of finalising licensing or sale agreements.

I would like to take this opportunity to provide further insight into our project developments, our achievements and our business development over the year.

To view the full announcement, please click on the button below.

YPB First Deal With Latest Channel Partner

22nd September 2016, ASX Announcement

Highlights:

  • Impact customer LaClinica for Skin & Body signed for YPB PROJECT solution
  • FMCG packager Impact International announced as Channel Partner in July 2016
  • Marketing campaign conducted by Impact in Augst 2016 Introducing YPB to its customer base

Brand Protection and Customer Engement solutions company YPB Group Limited (ASX: YPB) is pleased to announce that the channel partner Impact International has signed its first deal pertaining to YPB’s technology with its customer La Clinica for Skin & Body.

La Clinica for Skin & Body is a cosmeceutical skin care line with a focus on visible results, efficacy safety & organic ingredients.

To view the full announcement, please click on the button below.

Folkestone’s First Seniors Living Fund No.1 Closes Oversubscribed

22nd September 2016, Folkestone

Folkestone’s (ASX:FLK) real estate funds management subsidiary, Folkestone Real Estate Management Limited (FREML), announced today that the Folkestone Seniors Living Fund No.1 has closed oversubscribed.

The Fund has raised $25.66 million and acquired its first asset, Watermark Castle Cove, an award winning retirement living community on Sydney’s lower north shore, the first asset for its seniors living platform and the Folkestone Seniors Living Fund No.1.

To view the full announcement, please click on the button below.

Alcidion Secures $525k Contract with The NT Health Department

22nd September 2016, ASX Announcement

Highlights:

  • $525k contract for Alice Springs and Royal Darwin Hospitals.
  • Follows the recently awarded $1.7m for Miya Order Sets.
  • Apple iPad’s view Electronic Patient Records and highlight emerging clinical risk.
  • Optimises Patient Flow, Bed Management across Northern Territory.
  • Patient Flow Market set to grow from $USD678.4 Million by 2019

The Northern Territory Department of Health has signed a $525k contract with Alcidion Group Limited (ASX:ALC) to utilise the company’s technology across the Royal Darwin and Alice Springs Hospitals. The Northern Territory Department of Health employs 6,323 staff and manages five public hospitals, and is presently constructing the new Palmerston Regional Hospital, the Northern Territory’s most technologically advanced facility.

To view the full announcement, please click on the button below.

Proteomics International Receives FY16 R&D Tax Incentive

21st September 2016, ASX Announcement

Innovative biomarker research conducted by Proteomics International Laboratories Ltd (PILL, ASX: PIQ) has been boosted by the receipt of more than half a million dollars in research and development tax incentive for the 2015-16 financial year.

PILL’s sustainable business model sees the company use revenue generated from analytical services to fun pioneering research into next generation diagnostic tests and drug delivery.

This self-sustaining model adopted blue sky concepts with cash flow from day one, using revenue from services to cover operational costs and drive substantial investment in R&D.

To view the full announcement, please click on the button below.

Actinogen Medical CEO Interview

Actinogen Medical Ltd (ASX: ACW) is an Australian, publicly-listed early clinical-stage biotechnology company focused on the treatment of cognitive impairment and Alzheimer’s disease.

Actinogen is developing Xanamem™ as a novel treatment approach to Alzheimer’s disease and other age-related neurodegenerative diseases. Xanamem™ displays high potency and selectivity for inhibiting the activity of a key enzyme in the brain, which converts cortisone to cortisol. Cortisol is also known as the stress hormone, and elevated levels of cortisol has previously been linked to cognitive impairment. The pivotal human proof of concept study, also known as XanADu, commenced in 2Q2016.

Please listen to Dr. Bill Ketelbey, Founder and CEO & Managing Director of Actinogen Medical below.

Parrot Analytics in the News; Bloomberg, Asia TV Forum, Investopedia and More

14th June 2016, Bloomberg By Angus Whitley

Your Facebook Posts, Tweets Are Writing Hollywood’s Next Hit

Your Facebook posts and tweets may contain hidden creativity. In fact, they could be helping to write the next Hollywood blockbuster.

As once-monolithic television audiences splinter and migrate to the Internet, viewers have unwittingly turned the creative process upside down. Their social media posts, blogs and file downloads are telling streaming companies and producers what actors, writers and themes to weave together on-screen for the best chance of bottom-line success.

To read more, please click here.

5th August 2016, Asia TV Forum By Lunita S V Mendoza

Its Complicated Measuring Mammoths 

“To understand consumption these days, we need new data systems, new processes, new tools and new metrics,” said David Boyle, Executive Vice President of Insight at BBC Worldwide, a client of Parrot Analytics.

This becomes increasingly pertinent as the landscape of ‘television” evolves to greater heights of complications. Entities across the globe are taking the place of – if not adding on to – our beloved telly, the “boob tube”, “idiot box”, and yes, the “baby-sitter”.

To read more, please click here.

19th September 2016, Investopedia By By Rakesh Sharma

Streaming Services Win Big At Emmys (AMZN, NFLX)

It was a win for streaming services last night as they hauled in a total of 15 trophies at the Emmy awards last night. The personal brand of Jeff Bezos, founder of Amazon.com Inc. (AMZN), also received a major boost when he got a number of shout outs from awardees.

Amazon’s Prime streaming service won six awards as Transparent, a show which has already racked up wins in previous years, added two more to its tally last night. That tally included an award for best lead actor in a comedy.

To read more, please click here.

29th June 2016, Variety By Todd Spangler

Bruce Tuchman, David Bishop Join Board of TV-Data Startup Parrot Analytics 

Parrot Analytics, a tiny hatchling of a company that’s built a global system for measuring demand for TV content, has secured the backing of two notable Hollywood execs.

Joining the company’s board are Bruce Tuchman, former president of AMC Global and the Sundance Channel Global, and David Bishop, former president of Sony Pictures Home Entertainment and MGM Home Entertainment. Both also plan to invest in Parrot Analytics, but the size of their investment isn’t being disclosed; the startup says it’s currently in the middle of raising a round of financing.

To read more, please click here.

15th September 2016, Media Week By James Manning

Parrot Analytics: Measuring the global demand for TV content

Parrot Analytics is a New Zealand-based business that has gone global with its unique measurement of television programs being broadcast across all platforms.

Parrot has developed a measurement called demand expressions where programs from Netflix and other over-the-top (OTT) broadcasters are able to be compared to the demand for other shows delivered via traditional or other means to the audience.

To read more, please click here.

11th August 2016, Screen Daily By Jeremy Kay

Parrot Analytics, all3media International sign pact

EXCLUSIVE: The LA-based research firm has added another client to an expanding portfolio that includes BBC Worldwide.

UK-based distributor all3media International will use Parrot Analytics’ data science to add forensic insight to its global TV licensing operation.

To read more, please click here.

Sports Bridge CEO Interview

Sports Bridge is a self-promotional social platform which allows for people, business and organisations in sports to add real value to their brand through self-promotion, networking, education and a host of designed services within a unique and pure sports audience.

Currently there is vast demographical challenges for people in sport to not only promote themselves and actually be seen by the people who are looking to connect with them but also there is a clear gap in education between the professional level of sports and amateur levels restricting growth in sports. Sportsbridge.com and its unique value proposition, is disrupting the market and is now a proven demand with high initial membership growth through the MVP.

Please listen to Mr Westley Hallam, Founder and Managing Director of Sports Bridge below.

Fuel50 Reports Client Revenue Upsells & Investor Information Session

Fuel50 are launching their LeaderView edition at HRTech next month, already with recognition from industry analysts Starr Conspiracy, this edition has already been extended to the Westpac NZ Fuel50 program of work who now will be launching the leader edition, along with an increase in revenues of $22k. In the US, EBay committed to taking Fuel50 into the following languages over the next 6 months : Korean, Simplified Chinese, German and Turkish, which will add 2 to the current 20  languages that Fuel50 can be found in.  MasterCard evaluating their Priceless Careers Campaign, using Fuel50’s Leader Edition found that 86% of employees rated greater career satisfaction at MasterCard after utilising Fuel50 and a giant 25% improvement in manager ratings, which aligns with their Managers Matter program.

Fuel50 are hosting an Investor Information Session this Friday at 11am, to find out how they have grown to 60 clients, 22 languages and a $million recurring revenues.

To RSVP for this event, please click on the button below.

Oracle Names Suitebox As Platform Innovation Winner

  • SuiteBox’s client engagement solution for professionals wins prestigious global award at Oracle’s San Francisco OpenWorld event
  • SuiteBox named alongside cloud leaders Airbus, Avaya, Dubai Airports, Proctor & Gamble, Renault and State Bank of India among others

SuiteBox, the mobile office solution for professionals, has been honoured with a Cloud Platform Innovation Award.  SuiteBox was named as a winner at Oracle OpenWorld in San Francisco on Tuesday evening for its use of Oracle’s PaaS and IaaS services. The award reflects SuiteBox’s new and innovative use of the cloud, which it has used to transform its businesses, drive innovation, and gain a competitive advantage.

Ian Dunbar, SuiteBox CEO, said: “Oracle’s recognition of SuiteBox, alongside global PaaS and IaaS leaders recognises theuniqueness of our business case, business benefits, the potential impact of SuiteBox on professionals as well as the complexity and magnitude of our implementation, and the originality of our architecture.

“I’m delighted that Oracle has recognised SuiteBox at such a global and prestigious event. SuiteBox delivers huge value to professionals by allowing them to engage their clients more effectively by reducing the steps in business processes and through communication that is streamlined and digital. Our technology gives you the ability to reach in at any moment and interact with the people that matter most to you and your business; SuiteBox wants to partner with professionals around the globe to help achieve this.”

Amit Zavery, senior vice president of Cloud Platform and Integration products, Oracle said: “These awards recognize customers that are using Oracle’s PaaS and IaaS together in unique and innovative ways to transform their businesses. Over the past couple of years, we’ve seen our customers make a wholesale move in using the cloud for just simple dev/test scenarios to running serious, enterprise workloads in the cloud.”

In the past few months SuiteBox has opened regional offices in Europe, Asia Pacific and Southern Africa, and, in the next month, it will be announcing a raft of significant technology enhancements to the platform, as well as major enterprise client partnerships in key markets.

About SuiteBox

SuiteBox transforms customer engagement with intuitive video, document collaboration, selective recording and real-time digital signing, helping you accelerate and close business using the full power of mobile and desktop devices. It is able to be fully white labelled and seamlessly integrated with a client’s core CRM or banking platform.  SuiteBox is available via monthly subscription and is delivered via the cloud and requires no technical expertise to use.

Charter Hall Acquires 50% Interest in Coles Headquarters Melbourne

21st September 2016, ASX Announcement

Charter Hall Group (ASX:CHC) (Charter Hall or the Group) announces it has entered into an agreement to acquire a 50% tenants-in-common interest in the Melbourne office headquarters of Wesfarmers’ subsidary Coles, a long term occupant of the building which has recently signed a new 15 year lease expiring in 2030.

The purchase was negotiated directly off market from Investa Office Fund (OF), for a total purchase price of $140.5 million. The remaining 50% interest in the property is owned by a private group.

The property, known as the Coles Headquarters, is located at 800 Toorak Road, Hawthorn East, and is 100% leased to the Coles Group Limited for an initial 15 year lease term expiring 17 March 2030, plus options.

To view the full announcement, please click on the button below.

Mafematica CEO Interview

Based out of FinTech hub Stone & Chalk, Mafematica is an emerging company that was founded by a serial entrepreneur and financial services veteran. Mafematica has designed a scalable, high speed and low cost robo-advice service that is targeting the massive $590 billion SMSF market. It is aimed at helping accountants, planners and trustees to marry a choice of investments with their retirement planning.

The business is based on a financial calculator that projects retirement estimates based on the actual securities held including residential property. Mafematica has secured strategic partnerships in the Actuary and SMSF industries, and is backed by PwC. Its first product, a Retirement Income Report, will be producing revenue within 2 months.

Please listen to Mr Derek Condell, Founder and Managing Director of Mafematica below.

Mafematica SMSF Statistical Report June 2016 & Memo Brief

The June 2016 quarter statistical report on self-managed super funds (SMSFs) is now available. The report provides high level statistics on the population of SMSFs and members, estimates of total assets and of various asset classes held by SMSFs, as well as fund and member demographics.

Statistical highlights from the June 2016 quarter:

  • the total number of SMSFs is 577,236
  • total members of SMSFs is 1,087,841
  • total value of estimated SMSF assets is $621.7 billion.

ABOUT MAFEMATICA

Based out of FinTech hub Stone & Chalk, Mafematica is an emerging company that was founded by a serial entrepreneur and financial services veteran. Mafematica has designed a scalable, high speed and low cost robo-advice service that is targeting the massive $590 billion SMSF market. It is aimed at helping accountants, planners and trustees to marry a choice of investments with their retirement planning.

The business is based on a financial calculator that projects retirement estimates based on the actual securities held including residential property. Mafematica has secured strategic partnerships in the Actuary and SMSF industries, and is backed by PwC. Its first product, a Retirement Income Report, will be producing revenue within 2 months.

To download the Memo Brief, please click on the link below. 

Altech Chemicals HPA Project Detailed Design Update

21st September 2016, ASX Announcement

Highlights:

  • German M+W Group well advanced on HPA plant detailed design and engineering
  • Leading global engineering and construction firm with extensive Asian experience
  • Established Singapore and Malaysian offices, with extensive Malaysian construction experience

German M+W Group well advanced on HPA plant detailed design and engineering work that is currently being undertaken by German firm M+W Group in Stuttgart, Germany, for its proposed Malaysian high purity alumina (HPA) plant.

M+W Group is leading global high-tech engineering firm with around 6,000 employees worldwide. Established in 1912, M+W Group has a strong presence in Asia with regional offices in both Singapore and Penang, Malaysia.

To view the full announcement, please click on the button below.

Charter Hall Acquires $197m Campbelltown Mall for New Partnership

20th September 2016, ASX Announcement

Charter Hall Group (ASX: CHC) (the Group) has created a new wholesale property partnership for retail shopping centre assets, by co-investing with one of Australia’s largest super funds MTAA Super, who were advised by JGS Property, to acquire Campbelltown Mall in an off market transaction for a total purchase price of $197 million, reflecting a market capitalisation rate of 6.00%.

Charter Hall will manage the partnership, to be known as the Charter Hall Prime Retail Fund (CPRF), and the Group has committed to co-invest $46 million towards the acquisition of the property, representing an initial 38% investment with initial gearing at 45%.

To view the full announcement, please click on the button below.

BPS Technology Annual Report to Shareholders 2016

20th September 2016, ASX Announcement

Principal Activities

The principal activities of the consolidated group during the financial year were to provide and licence technology platforms that drive customers to merchants. The group earns fees from members that transact on these platforms.

The operations are conducted in Australia, UK, New Zealand and the USA.

Significant Changes to Activities 

There were no significant changes in the nature of the consolidated group’s principal activities during the financial year.

To view the full announcement, please click on the button below.

Recording of Crowd Mobile’s Investor Webinar and Teleconference

20th September 2016, ASX Announcement

Crowd Mobile Limited (ASX:CM8 & FWB-XETRA: CM3) (Crowd Mobile or the Company) refers to the investor webinar and teleconference held on Monday 19 September 2016 at 4.30pm AEST regarding Crowd Mobile’s financial results for the year ended 30 June 2016. Crowd Mobile advises that a recording of this webinar and teleconference has been made available on the Company’s website.

The recording can be assessed at:

crowdmobile.com/media

To view the full announcement, please click on the button below.

Invitation: H2Ocean Information Evening

You are invited to the H2Ocean Limited Information Evening 

RSVP here if you would like to attend a free information evening, which will be held at Stone & Chalk in Sydney on Tuesday the 27th of September from 5.30pm, to learn more about H2Ocean.

H2Ocean is a first-to-market Listed Venture Company that will invest in between 15 - 50 early stage and growth stage fintech companies. These companies look to offer new and better products, services and business models, and have the potential to become major financial services industry participants in the future.

Investors in the H2Ocean IPO will be entitled to participate in the H2Ocean Private Syndicate. Administered by Equitise, the H2Ocean Private Syndicate will allow private investors to access direct Fintech ventures alongside H2Ocean. This is a unique way for all investors to access Fintech venture investments.

Key Highlights 

  • Access unlisted fintech investments in a globally diversified portfolio;
  • Invest alongside leading venture investors;
  • The potential to hedge existing bank exposure within a portfolio;
  • Under the leadership of an experienced investment team and Board.

IPO Details

H2Ocean is seeking to raise a minimum of $27.5 million and a maximum of $55 million through the issue of ordinary shares at a share price of $1.10. Each share will have a free attaching option that will vest on the first anniversary of official quotation to the ASX and are exercisable on a one-for-one basis on or before 19 April 2018.
The Investment Manager

The Manager of the portfolio, H2 Ventures Pty Limited, is led by founding partners Ben Heap and Toby Heap. Both are experienced fintech investors, bringing over 30 years of expertise with respect to financial services and principal investment. The Manager estimates that the Portfolio will take approximately 18 months to fully construct and is expected to consist of between 15 and 50 investments.

In the short to medium term, the Manager will be responsible for identifying and investing the Company’s funds in early and growth stage Fintech Ventures. In the longer term, the Manager intends to proactively seek opportunities to exit these investments when there are financially attractive opportunities to do so.

To RSVP for this event, please click on the button below.

Peppermint Q&A; Video with Managing Director Chris Kain

20th September 2016, ASX Announcement

Peppermint Innovation Limited (“Peppermint” or “the Company”) is pleased to advise shareholders of the opportunity to view a Q&A video with Managing Director Chris Kain.

Peppermint is an ASX-listed fintech company who has made a mobile banking and payments platform currently deployed and used by major banks, along with an agent network for the unbanked, where it has been proven, is now being ramped up and has started to generate revenue.

To view the full announcement, please click on the button below.

To watch the video, please click on the button below.

SUDA Investor Road Show Presentation September 2016

20th September 2016, ASX Announcement

a leader in oro-mucosal drug delivery, today announces that Mr. Stephen Carter, Managing Director and CEO, and Mr. Nick Woolf, Chief Business Officer, are meeting with investors, brokers and analysts in Brisbane, Sydney and Melbourne from 20-23 September 2016.

Overview

  • SUDA (ASX: SUD) is a drug delivery company commercialising low-risk pharmaceuticals
  • Extensive proprietary technology, expertise and knowhow in formulating and manufacturing oral sprays
  • Multiple patent families covering approx. 300 widely-used drugs formulated into oral sprays
  • SUDA’s first-in-class oral sprays have demonstrated meaningful advantages vs. standard-of-care tabletsin multiple clinicalstudies
  • Multiple oral sprays for large markets – insomnia, malaria, migraine, erectile dysfunction, chemo-induced nausea

To view the full Presentation, please click on the button below.

Silicon Controls and Thinxtra to Connect 1 Million Monitoring Devices for Oil & Gas Industry to SIGFOX Internet of Things Network

19th September 2016, Business Wire

SIGFOX seamless connectivity will allow Silicon Controls to offer global monitoring solutions for tanks and cylinders wherever the network operates

Silicon Controls, a global leader in tank & cylinder monitoring devices (GASLOG™), SIGFOX, the world’s leading provider of dedicated communications service for the Internet of Things (IoT) and Thinxtra, the exclusive SIGFOX network operator (SNO) for Australia & New Zealand, announced today a strategic partnership agreement. As part of the agreement, Silicon Controls and Thinxtra will work together to connect Silicon Control’s next-generation remote monitoring equipment to over 1 million tanks and cylinders via the long-range, low-power SIGFOX network.

Already working on opportunities in Europe, Asia Pacific and North America, the scope of the agreement includes the focused development of Silicon Controls’ IoT monitoring equipment, leveraging SIGFOX’s connectivity solution and know-how, network expansion, development of joint go-to-market solutions and SLA-based operational support to customers.

To view the full article, please click on the button below.

BioDiem Annual Report & Notice of Meeting 2016

NOTICE OF GENERAL MEETING 

Notice is given that the Annual General Meeting of Members of BioDiem Limited (“BioDiem” or the “Company”) will be held at the offices of Grant Thornton, Wills Room, The Rialto, Level 30, 525 Collins Street, Melbourne VIC 3000 on Wednesday 19 October 2016 at 1:30pm (AEDST).

AGENDA

The Explanatory Statement and proxy form which accompany and form part of this Notice, describe in more detail the matters to be considered. Please consider this Notice, the Explanatory Statement and the proxy form in their entirety.

ORDINARY BUSINESS

Receipt and consideration of Accounts & Reports To receive and consider the financial report of the Company and the related reports of the Directors and auditors for the year ended 30 June 2016.

Note: There is no requirement for shareholders to approve these reports. Accordingly no resolution will be put to shareholders on this item of business.

To view the full announcement, please click on the button below.

Actinogen Medical’s Understanding Alzheimer’s Event

Actinogen Medical looks forward to seeing you at our “Understanding Alzheimer’s” Symposium in Melbourne this Wednesday! Don’t forget to RSVP to reserve your spot, if you haven’t done so already – we’re sure it will be a meaningful event.

The Brains Behind Saving Yours
Alzheimer’s disease is one of the greatest health issues of our time. Join us on World Alzheimer’s Day to hear from leading experts in Alzheimer’s research and individuals experienced in coping with the burden of the disease. They will be discussing all aspects of Alzheimer’s including the progress being made in developing effective treatments for this devastating condition.

Speakers
Dr. Bill Ketelbey CEO & Managing Director,Actinogen Medical

Anne Fairhall Carer Advocate, Alzheimer’s Australia Vic

Professor Colin Masters The Florey Institute & University of Melbourne Professor

Ralph Martins McCusker Foundation & Edith Cowan University

Event Details
Novotel Melbourne, 270 Collins Street 5:30pm – 7:30pm Wednesday, 21 September, 2016

Crowd Mobile FY16 Results Webinar and Teleconference

14th September 2016, ASX Announcement

Crowd Mobile Limited (ASX: CM8& FWB-XETRA: CM3) will hold an investor webinar and teleconference to outline highlights of the full year results for the financial year ended 30 June 2016.

The webinar will be held 19 September 2016 at 4.30 pm AEST.

To join the webinar please register at: http://tinyurl.com/CM8FullYearResults

To view the full announcement, please click on the button below.

SUDA Letter to Shareholders September 2016

13th September 2016, ASX Announcement

SUDA Ltd (ASX:SUD), a leader in oro-mucosal drug delivery, today published its sixth shareholder newsletter, which will be mailed to shareholders.

Mr Stephen Carter, Chief Executive Officer of SUDA said: “The newsletter is a valuable forum for us to put recent news in context; to highlight upcoming events; and to set out in more detail the progress and activities at SUDA.

“In this newsletter, we provide an update on business development activities as we advance towards our first commercial agreements. We describe the progress with ZolpiMist™, our oral insomnia spray, including the successful re-launch in the US and our plans to manufacture and register this unique product in Australia.”

To view the full announcement, please click on the button below.

Analytica’s Pericoach Published in Journal of Urology and Research

15th September 2016, ASX Announcement

Analytica Ltd (ASX: ALT) continues to execute their strategy for demonstrating PerCoach® clinical efficacy with the company’s latest publication in the internationally regarded Journal of Urology and Research.

The case study details the experience of a 70-year old female with Multiple Sclerosis (MS) and faecal incontinence using PeriCoach as an adjunct treatment to her physical therapy sessions. The study is authored by Physical Therapist Dawn Sandalcidi, RCMT, BCB-PMD who sepcialises in orthopaedic manuel therapy and pelvic muscle dysfuntion treatment, and is the owner of Physical Therapy Specialists in Colorado. Ms Sandalcidi is a member of Analytica’s US Clinical Advisory Board.

To view the full announcement, please click on the button below.

BPS Completes Acquisition of Entertainment Publications

15th September 2016, ASX Announcement

BPS Technology Limited “BPS” (ASX:BPS), is pleased to announce that the acquisition of the shares in Entertainment Publications of Australia (Pty) Ltd and Entertainment Publications Limited in New Zealand that was first announced on 12 August 2016 has now been successfully completed.

 

To view the full announcement, please click on the button below.

ABOUT BPS TECHNOLOGY 

BPS Technology Limited (ASX: BPS) provides technology and payment platforms centred on SME’s. It is a profitable business operates in eight countries, capitalising on a number of significant growth opportunities.

BPS operates three highly complementary and scalable businesses – Bartercard, bucqi and TESS.

Bartercard operates the world’s largest trade exchange. It allows SME’s to conduct $600m of additional business without the use of cash.

Caldera Says Third Study of PSA-Test Alternative Shows High Ability to Spot Prostate Cancer

15th September 2016, NBR By Jonathon Underhill

Caldera Health, a New Zealand biotech company working on a gene-sequencing replacement for the world’s most widely used prostate cancer test, says its third clinical test has shown a strong ability to identify prostate cancer and screen out those who test negative.

The company is working on a replacement for the widely used PSA blood test with a simple “pee in a pot” test, using RNA biomarkers. In 2012, the US Preventive Services Task Force recommended against mass PSA screening because it threw up both false positives and negatives, didn’t distinguish between aggressive cancers and benign strains or even other prostate conditions, and led to over-diagnosis and unnecessary prostatectomies.

To view the full article, please click on the button below.

Aussie Fashion App ‘Stashd’ Makes Chinese TV Debut

22 April 2016, SBS

Fashion app entrepreneur Jess Wilson always had high aspirations for her business but the speed of her expansion into China has taken her by surprise.

Ms Wilson, creator of the fashion discovery and shopping app “Stashd”, is about to showcase her business smarts to millions of TV viewers on Chinese reality TV show The Next Unicorn.

Dubbed a cross between The Shark Tank and The X-Factor, The Next Union pits 55 start-ups against each other in the hunt for a future $1 billion tech behemoth – a “unicorn” in start-up language, with $2.5 million prize money on the line.

To view the full article, please click on the button below.

To receive offer, please click on the button below.

MedAdvisor Acquisition and Fund Raising Presentation

12th September 2016, ASX Announcement

MedAdvisor Limited (ASX: MDR, the Company) today provides its acquisition and fund raising presentation following the announcement on the 31 August 2016 that it has entered into an agreement to acquire 100% of Health Enterprises 2 Pty Ltd, trading as Healthnotes.

To view the full announcement, please click on the button below.

ABOUT MEDADVISOR

MedAdvisor International Pty Ltd (“MedAdvisor” or “the Company”) is an Australian medical technology business focused on designing and commercialising world class software platforms for medication management on mobile and internet devices.

MedAdvisor’s Platform connects to pharmacy dispensing systems, automatically retrieving medication records and driving an intelligent training, information and reminder system to ensure correct and reliable medication use.

Arthritis Relief Plus Selected by Australian Government for Entrepreneurial Program

12th September 2016, Chiropractic Economics

Millions of Americans and others worldwide who suffer from joint pain including osteoarthritis will soon get access to a remarkable topical product developed with natural botanical extracts but supported by gold standard scientific research. The patented technology in 4Jointz has been published in leading peer-reviewed medical journals after successfully completing clinical studies in Australia and the U.S.

Australian-based Arthritis Relief Plus Ltd (ARP) is one of only eight companies recently selected by the Australian Government for its entrepreneurial “Landing Pad” program, a highly competitive initiative for fast-expanding companies with global potential, located at San Francisco tech accelerator RocketSpace. In August, RocketSpace, which helped Uber, Spotify and other startups, raised $336 million to expand into international markets.

“We’re thrilled to finally be able to offer this robustly-tested, natural OTC topical to Americans and sufferers worldwide for the first time,” said Andrew Loch, CEO of ARP (USA) Pty Ltd. “This product is unique—there’s nothing like it on the market—and we greatly appreciate the community support we are receiving for our launch of 4Jointz.”

Part of what got 4Jointz to where it is today, preparing for a major launch on Indiegogo, is strong support from people who have experienced significantly improved quality of life as a result of using 4Jointz.

To view the full article, please click on the button below.

OncoSil Medical Annual Report 2016

12th September 2016, ASX Announcement

FY16 Achievements Delivered

September 2015 

Submission of CE Mark application for OncoSil™

October 2015

OncoSil™ CE Mark application granted Fast Track review status

December 2015

Investigational Device Exemption (IDE) submitted to the U.S. FDA for OncoPac-1 clinical study

January 2016

Chris Roberts appointed Independent Non-Executive Director

February 2016

$10 million private placement to Regal Funds Management

March-April 2016 

Q-Submissions meeting with FDA

Responses to CE Mark and FDA questions

May 2016 

OncoSil Medical completes hiring of senior management for Leadership team

To view the full announcement, please click on the button below.

Vinomofo Partners with Programmatic Advertising Software Platform TubeMogul

12th September 2016, B and T

After raising $25 million in financing earlier this year, Vinomofo sought an advertising technology partner with tools to drive continued domestic growth and also launch in new global markets.

The brand went live in New Zealand in August and has its sights firmly set on Britain, the United States, Singapore, Hong Kong and China.

Vinomofo’s head of marketing, Kip McMillan, said it was vital for the retailer to partner with a company that has a strong global presence and capabilities.

“TubeMogul’s software provides access to key international markets from the one console in the comfort of our Melbourne office,” he said.

“The scale, control and workflow efficiencies allow us to strengthen our branding efforts where our customer base is – online.

“TubeMogul’s position as an independent, customer-focused platform is something we relate to and really value. We saw a lot of similarities in our culture and approach to doing business. Each interaction with the Tube team seemed to embody our Vinomofo ethos to step up, care more, keep it real, do some good and have fun.”

To view the full article, please click on the button below.

Crowd Mobile Rights Issue and Management Restructure

12th September 2016, ASX Announcement

Rights Issue

Crowd Mobile Limited (Crowd Mobile or the Company) is pleased to announce that it is undertaking a pro-rata partially underwritten non-renounceable rights issue (Offer or Rights Issue)

Key highlights of the Rights Issue:

  • Rights Issue on a 1:18 basis at an issue price of $0.16 per share to raise circa $1.5 million
  • Free attaching options on a 1:2 basis for new shares issued under the Rights Issue. The attaching options will be exercisable at $0.27 each and will expire 2 years from their date of issue
  • Offer partially underwritten up to $600,00, with shortfall facility to enable applications for additional shares

To view the full announcement, please click on the button below.

4Dx Closes $500k Retail Funding Round to Add to $4M in Wholesale Capital

Innovative med-tech company 4Dx is a step closer to commercialising its four-dimensional lung imaging technology after successfully closing a $500,000 retail raise fully subscribed. This comes in addition to the company already raising AU$4m in capital from private investors which will be used to advance the business beyond initial FDA clearance early next year.

4Dx’s lung imaging technology has the potential to play a major role in the diagnostics and treatment of respiratory diseases such as asthma, chronic obstructive pulmonary disease, cystic fibrosis and lung cancer.

The close of the retail round brings the total funds invested in this technology to Over $15million which includes backing by 4Dx investors, grants and R&D tax incentives and US$600k from the sales of a pre-clinical scanner to a major U.S Hospital.

Folkestone Maxim A-REIT Securities Fund – August Monthly Report

August 2016

Over the 12 month period ended 31 August 2016, the Fund returned +29.71% (after fees, before tax), outperforming the Benchmark return of +25.95% by +3.76%.
The Monthly Report provides a snapshot of the Fund and the A-REIT sector’s performance.
Read more

A-REIT REPORTING SEASON

What Did We Learn From The A-REIT Reporting Season?
A-REITs have performed strongly in recent years.
The obvious question is whether this level of outperformance is sustainable and can A-REITs outperform the other major asset classes for a third consecutive year.
So what did the recent August reporting season tell us about the health of the A-REITs and more importantly what lies ahead?
Read more

A-REIT SECTOR PERFORMANCE

August 2016
A snapshot of key A-REIT performance graphs for the month of August.
Read more

The Folkestone Maxim A-REIT Securities Fund is a high conviction, actively managed fund, that gives investors exposure to a mix of quality listed A-REITs that own assets across the retail, residential, commercial, industrial and real estate related social infrastructure sectors.

  • Investment Expertise
  • Exposure to Listed Real Estate
  • High Conviction, Active Strategy
  • Daily Liquidity
  • Quarterly Distributions
  • Strategic Capacity Limit

Download PDS

Leaf Resources Annual Report to Shareholders 2016

9th Septemebr 2016, ASX Announcement

The year’s activities culminated in the signing in July 2016 of a global partnership agreement with Claeris LLC of Dallas, a successful renewables project developer, to build up to five biorefineries.

The principals of Claeris have considerable experience in developing and negotiating financing for renewable chemical projects. They are also extremely well credentialed and connected within the world-wide renewable market. By partnering with an experienced project developer such as
Claeris, the Leaf Resources’ Board believes we have accelerated the development of revenue generating projects, reduced the financing risk and that we will achieve better commercial outcomes. The partnership represents a major milestone in the technology development and commercialisation path that Leaf Resources has embarked upon.

It is especially gratifying that Claeris, after searching the world to find the right technology for renewable chemical projects discovered Leaf Resources. It is also testament to the considerable work over the last 12 months, that Leaf Resources was able to satisfy the extensive requirements of due diligence conducted by Claeris, and especially that our GlycellTM process is ready for commercialisation and able to support the necessary financing arrangements that come with any large construction project.

This agreement with Claeris adds to previously announced agreements with Monaghan Mushrooms, ZeaChem and the innovative work done on removing Silica from rice husk, thereby positioning Leaf Resources with an attractive and valuable list of potential projects.

To view the full article, please click on the button below.

YPB Signs Three-Year, Million Dollar Contract with Leading Pharma Company

9th September 2016, ASX Announcement

  • YPB to provide Brand Protection to Combiphar using the YPB CONNECT platform – expected to be implemented initially across tens of millions of products annually
  • Expected revenue of approx. A$1m over the term of the three-year agreement
  • Combiphar is a leading supplier of prescription and over-the-counter pharmaceuticals with around 170 product lines

Brand Protection and Customer Engagement solutions company YPB Group Limited (ASX: YPB) has signed a three-year agreement with leading Indonesian pharmaceutical and wellness company Combiphar for the supply of Brand Protection solutions in Asia.

YPB expects the three-year agreement to generate revenues of approximately A$1 million, with YPB technology to be applied to tens of millions of Combiphar products per annum over three of its 170 product lines.

To view the full article, please click on the button below.

Meme Capital Factsheet and Performance Review

INVESTMENT OBJECTIVE:

To outperform the S&P/ASX All Ordinaries Accumulation Index over rolling three year periods, through active investment in ASX listed securities outside the S&P/ASX 20.

INVESTMENT APPROACH:

The Fund takes an evidence-based quantitative approach to investing and uses a robust and back-tested trend-following strategy to identify investment opportunities expected to provide both positive price appreciation and relative price outperformance over the medium to long term. The Fund rigorously applies a set of capital management rules to manage both risk and return such that any losses are taken while they are small while gains are given room to compound until their long term price trends become exhausted or their relative out-performance becomes impaired. The Fund employs a non-thematic, bottom-up investment style which allows us to quantify both the absolute and relative merits of each investment opportunity and to allocate the Fund’s investment capital accordingly. The resulting exposures to the various market sectors are essentially a consequence of that process, such that the strategy at the individual investment level guides the Fund’s sector exposure and not the other way around. The Fund only takes long positions and does not use derivatives. The Fund will hold an allocation to cash to the extent that there are at any time insufficient investment opportunities at appropriate levels of risk.

To view the full article, please click on the button below.

Alcidion to Host Product Overview Webinar

8th September 2016, ASX Announcement

  • Alcision Product Overview Webinar, Wednesday, 14 September 2016
  • 12.30pm AEST Sydney/Melbourne/Brisbane;
  • 10.30am AWST Perth Time;
  • 12.00pm ACST Adelaide/Darwin Time

Alcidion Group Limited (ASX:ALC) today announced that it will hold an investor webinar on Wednesday, 14 September 2016 to present the product portfolio to investors.

Alcidion’s Chief Medical Officer and Co-Founder, Professor Malcolm Padhan will host the webinar, which aims to give investors a broad understanding of Alcidion products and the complex healthcare problems the company solves with its Clinical Depression Support platform, Miya.

To view the full announcement, please click on the button below.

iCompLii September Shareholder Update

September is already upon us, and as iCompLii powers on, improving, reinventing and strengthening,  its a great time to have an update!

General Update

We have whizzed by our second birthday as iCompLii Ltd and the company has been going through quite a few changes. We are restructuring both the Board of Directors and the day to day operational business unit at the moment. This restructure has both been suggested to us and is required to facilitate our transition from a proven concept to an organisation that is growing into a commercially sustainable entity.

As part of the restructure, two of our junior board members have stood aside to make room for more experienced and prominent board members, so I would like to take this moment to formally thank Michael Carew and Dave McVicar for their efforts and assistance both as directors for the last year and for their substantial energy and commitment to the company for the last several years.

The ISC ( independent sales consultant ) marketing system is well and truly up and running with several external ISC’s now registered and promoting iCompLii. There has been around 100 referred profile holders in just the first month of operation, which is really promising for growing the database.

Sales by external ISC’s are the next target and we are talking to several companies via external ISC’s and the first contracts are very close.

Releasing iCompLii, a new concept and platform as a network marketed arrangement has had quite a few challenges. However, we have skipped through them fairly quickly and we are now able to reach small and micro organisations, which are normally unreachable with traditional sales teams that require ticket prices consistent in clients with excess of several hundred employees.

Strengthening the Board of Directors

We have received feedback from investors to the effect that the Board of Directors is not as strong as it could be at our stage of development, and that they would like to see improvement in this area. As such, several months ago we started planning to simplify the iCompLii Board of Directors, to make way for experienced and/or professional non-executive directors and an external chairman.

Therefore we are currently looking for candidates for potential roles on the iCompLii Board of Directors. Ideally we are looking for people with at least one or more of the following attributes.

  • Successfully exited a tech startup
  • Experienced director of a tech startup
  • Experienced at fund raising activities for tech startups
  • Well connected person in the safety/training/tech sector
  • Well connected C-Level executive in
    • Human Resources company
    • Regulated or compliance heavy sector
    • Compliance

iCompLii potential acquisition

We currently have several companies that are looking at iCompLii as a potential acquisition. Meetings and initial talks have already taken place and whilst they are early, this shows that iCompLii is being noticed. Even without a formal offer as an end result, it is a sign that larger companies are starting to really take notice. therefore It is quite a good possibility that in the medium term a complimentary company could become an equity stakeholder further improving our position.

Acquisition for growth

iCompLii in addition to being vetted as a potential acquisition, is investigating several startups as potential acquisition targets to accelerate the growth and traction of iCompLii. Going down this road could increase our strength by further expanding network, sales and/or capabilities.

One such startup we are well into talks with, is a complimentary concept that has a prototype and a very similar big picture vision to those that are the driving force behind iCompLii. This is an exciting proposition for both companies, as together we are a much stronger unit with considerably more reach, larger networks and much more diverse skill set.

Development advances

The iCompLii website has progressed quite substantially of late, with further additions and modifications increasing the usability and value proposition for our clients.

Some of the most significant enhancements are;

  • Addition of the ISC management console
  • Addition of the custom built in sales CRM
  • Finalising of the hosting environment modifications
  • Modification to the functionality of users adding personal motor vehicles
  • Addition of the businesses able to add equipment
  • New home page designs
  • Addition of custom landing pages to populate client candidate pools
  • Improved worker management page for business admins
  • Apps released to apps stores ( See below )

Apps now released on App Stores

iCompLii has now also released apps for both Apple and Android devices! This has cut the technology barrier of entry for candidates and workers creating a profile, as well as simplifying the populating of information into a profile. It has also added referral functionality that is working nicely, with steady referrals now happening through the apps functionality.

The apps allow workers and candidates to carry with them in a structured arrangement all their tickets, qualifications and other credentials, so if challenged, they can present a digital copy with image of the documentation in question.

iCompLii is pitching again at the September WI Sydney event

iCompLii is booked in for our 2nd round of pitching at the Wholesale Investor & ASX Emerging Company Showcase September 2016 which is being hosted at the ASX exchange in Sydney, Thursday the 15th of September. More information is available via this link.

Discussions with government.

Dialogues are now open with several departments throughout federal, State and local governments for both potential engagement and assistance. iCompLii is working towards becoming both a supplier and engaging with available assistance to enable us to grow and commercialise at a faster and more effective rate.

Fund raising continuing

During August, it was announced that we have made our minimum raise which was set at $170k. The current raise maximum was set at $510K and as such we have extended the close date, further enabling interested parties to assess the opportunity,  therefore there is still shares available for both old and new investors.

We are currently in discussions with several investors that are interested in what iCompLii is doing, these are early discussions, however with a stronger Board of Directors, we believe these will be more fruitful.

Alan Kohler Features Booodl on The Constant Investor

A little while ago Booodl CEO and Co-Founder, George Freney, was interviewed by Alan Kohler for Qantas Radio. The interview has gone live in the podcast section on The Constant Investor (Alan’s personal website) and we’ve just got our hands on a copy!

It’s Booodl’s mission to help physical retail thrive by driving shopper visits for retailers, brands and malls. They are very proud to share that since February they’ve been directly responsible for sending 17K shoppers into stores selling what they want.

Thinxtra Raises $11m in 5 Months

9th September 2016, Thinxtra

Internet of Things (IoT) start-up Thinxtra, has successfully completed its first significant round of venture capital financing, raising AUD11 million within five months of the initial round offer. The main investors include NZX-listed, technology company Rakon and a number of private investors including major players within the IoT space.
Thinxtra is empowering Australia and New Zealand’s Internet of Things by deploying SIGFOX, the most mature LPWAN* technology and the backbone to Internet of Things in terms of connectivity. SIGFOX has global coverage, with 24 countries deployed or being deployed (including USA, Australia & New Zealand)

Thinxtra has made rapid progress with rolling out the network in Australia and New Zealand. In Australia, 33% of the population is now SIGFOX covered while in New Zealand coverage has reached 54% of population, which has been achieved in just five months. The company is on track to provide coverage to 85% of all Australians and New Zealanders by the end of June 2017.

To view the full article, please click on the button below.

Alcidion to Present at WA Broker Meets Biotech

8th September 2016, ASX Announcement

Alcidion Group Limited (ASX:ALC) today announced that it will present at the AusBioTech WA Broker Meets Biotech Lunch on Thursday, 15 September 2016.

Executive Director, Mr. Nathan Buzza will present to brokers, investors and financial advisors, on behalf of Alcidion. Updating the group on the latest developments within the company, since being publicly listed in February 2016.

This event will be hosted by Mr. Brian Leedman, Co-Chairman of AusBiotech WA and Non-Executive Director to Alcidion GroupLimited.

It will feature a keynote presentation form Mr. Mark Dehring, Head of Investor Relations for CSL Limited, an overview of the biotechnology industry investment landscape from Mr. Stuart Roberts, Life Sciences Analyst at NDF Research.

To view the full announcement, please click on the button below.

BPS Technology & GetCapital Partner to Offer Finance Products Worth $100M to Merchants

8th September 2016, Proactive Investors

BPS Technology Ltd (ASX:BPS) has launched a new business finance product to support and enable its small and medium enterprises (SME) merchant partners.

More than 36,000 SMEs transact in excess of $600 million per annum using BPS’ software and trade exchange technology platforms.

The company has executed a new agreement with Get Capital Pty Ltd, a fintech lender, which will make available a range of finance products to BPS’ 36,000 merchants.

As part of the agreement, GetCapital will provide up to $100 million over the initial year of the agreement to support the partnership.

BPS Financial Ltd, a subsidiary of BPS Technology, will market the tailor-made finance products to its merchant base.

To view the full article, please click on the button below.

Actinogen Invitation: Understanding Alzheimer’s Event

The Brains Behind Saving Yours
Alzheimer’s disease is one of the greatest health issues of our time. Join us on World Alzheimer’s Day to hear from leading experts in Alzheimer’s research and individuals experienced in coping with the burden of the disease. They will be discussing all aspects of Alzheimer’s including the progress being made in developing effective treatments for this devastating condition.

Speakers
Dr. Bill Ketelbey CEO & Managing Director,Actinogen Medical

Anne Fairhall Carer Advocate, Alzheimer’s Australia Vic

Professor Colin Masters The Florey Institute & University of Melbourne Professor

Ralph Martins McCusker Foundation & Edith Cowan University

Event Details
Novotel Melbourne, 270 Collins Street 5:30pm – 7:30pm Wednesday, 21 September, 2016

Suitebox Announces UK Office And Appoints EMEA Head to Accelerate Growth

5th September 2016

SuiteBox, the mobile office solution for professionals, has opened an office in London and appointed Ian Little to lead its EMEA growth efforts.

SuiteBox delivers a new customer engagement channel for professionals that occupies the significant gap between face-to-face meetings and other forms of communication. SuiteBox has gained traction among professionals who desire more face-to-face time with clients, but find it increasingly difficult to schedule physical meetings. It is the only video meeting technology solution that allows you to share, amend and digitally sign documents with your customers in real time and with full compliance. It allows professionals to talk to their customers more frequently, in a more personalised and cost effective manner

Ian Dunbar, SuiteBox CEO, said: “I’m delighted to be growing our business reach and offering UK professionals the SuiteBox solution, which delivers huge value by reducing the steps in business processes, through communication that is streamlined and digital. Our technology gives you the ability to reach in at any moment and interact with the people that matter most to you and your business and SuiteBox wants to partner with professionals around the globe to help achieve this.”

“Face-to-face meetings are a significantly more valuable use of time for professionals, particularly as they look to build trust and personal relationships with clients, but also from a compliance perspective. With additional compliance requirements over the past few years, professionals and customers feel the pain every time you need to complete and return paperwork. It really slows down business processes and adds cost to the business. SuiteBox solves this problem by using digital signatures for on-screen authentication to complete transactions immediately. No more sending an email and waiting days or weeks for a response.”

Long Pipes: Will Steel Pipelines Become Obsolete?

Long Pipes objective is the elimination of corrosion; using its “No Joints” continuous composite pipeline the “Fluid Highway™”.

This composite pipeline is designed to be constructed on site without joints it is “spliced” together to form a continuous, joint free, corrosion resistant inner liner, composite reinforcements and a corrosion resistant outer casing that provide the pipeline with unique properties making it suitable for the transportation of extremely corrosive fluids; such as high temperature brines and sulphurous steam for geo thermal power, to raw CO 2 liquid directly from coal fired power stations for geo sequestration. This is in addition to its normal applications for the long distance transportation of fluids: gas (sour), oil (sour), water and slurry transport.

The total elimination of all materials degradation in every form forever, is impossible; however the composite pipeline comes closest to this objective using its unique continuous construction technology. With its inner and outer corrosion protecting the reinforcements; carbon, basalt, glass or Kevlar embedded in a Vinyl Ester resin matrix are free from attack from the fluids being transported and the external environment.

Using this system, we as engineers can now design long and short distance transportation networks to handle high pressure corrosive and abrasive fluids from nuclear power plants to irrigation networks and expect them to be maintenance free for decades, to generations to come.

LatAm Autos Beats Broker Forecast for 1H16

LatAm Autos has recently released its 1H16 Investor Presentation, click here to view it. Canaccord has also reiterated its 12 month price target of A$0.52 in a new report titled “The race to profitability”. To view the complete Canaccord report for LAA click here.

LatAm Autos Limited
Software and Services | Company Update
The race to profitability

LAA-ASX | Price A$0.22 | Market Cap A$65.6M
SPECULATIVE BUY Unchanged
PRICE TARGET A$0.52 Unchanged

Canaccord Genuity (Australia) Limited was a Joint Lead Manager to the two-tranche placement of ~15.38 million shares at $0.31 per share to raise A$18 million in October 2015 and ~6.9 million shares at $0.31 per share to raise A$2.2 million in December 2015 (subject to shareholder approval).

LAA is in the process of building a leading dedicated online auto classifieds and content platform with operations in Mexico, Argentina, Peru, Ecuador, Bolivia and Panama. 

LatAm Autos “LAA” released its 1H16 results that were ahead of CGau expectations at the revenue and EBITDA levels. The result illustrated considerable momentum in the business, not just from an operational standpoint but also from a revenue perspective across its major regions. The result was negatively impacted by a sharp depreciation in the MXN (-15%) and ARS (-35%) during the period; however, on a constant currency basis LAA reported regional revenue growth between +70% (Mexico) and +24% (Peru).

  • 1H16 revenue of A$3.9M was above our estimates (CGAu est. A$3.6M, 1H15 $2.7M) with LAA reporting an effective cash balance of $12.7M. 1H16 EBITDA, excluding discretionary marketing spend, was reportedly just -A$2.3M. Because of the positive commentary coupled with growth initiatives planned for the 2H, we remain comfortable that LAA is on track to meet our FY16 revenue forecasts (A$9.6M). Similar to previous periods, we expect LAA revenue profile to be skewed to the 2H (1H:2H 40%:60%).
  • Online revenues now account for >80% of group revenues, with a big drive into interactive mobile apps (consumers/dealers), a key differentiator versus regional competitors. Notably, lead generation to OEM’s, new car dealers, finance and insurance providers is becoming an incrementally meaningful revenue stream. The launch of its PTX Live is expected to drive increased engagement/usage of its platform/website.
  • LAA materially improved its market positioning in 1H16, with unique monthly views (10M in Jun-16 vs. 7.5M in pcp), listings (186k in Jan-16 vs. 107k in pcp) and dealers using its platform (3.0k in Jun-30 vs. 1.6k in pcp.) all growing strongly. We are attracted to the quantum of car dealers utilising LAA’s platform, enabling further value-added products to be distributed to the dealer network in future periods (valuation, insurance, certification, payments etc.) and increase the net take-rate to LAA.
  • Management highlighted they are positioning “LatAm Autos for continued strong growth in the second half of 2016” with management flagging a number of new revenue streams (7x) to be delivered in 2H16. Management reiterated its guidance to be profitable on a run-rate basis in 2018 (>A$20M revenue), highlighting that the company is expected ~50% revenue CAGR over the coming 2.5yrs.
  • The company is building a defensible market position that is likely to have a strategic benefit to global portal providers in future periods. Our forecasts have been marginally adjusted following revisions to our expense assumptions. Our DCF valuation remains unchanged at A$0.52ps.

Real Estate Investar’s Clint Greaves Increases Stake on Market

7th September 2016, Proactive Investors 

Real Estate Investar Group Ltd (ASX:REV) managing director and CEO, Clint Greaves, has increased his stake in the company through on-market purchases.

Hillier purchased 100,000 shares at $0.05 per share, lifting his combined direct and in-direct stakes to circa 5 million.

REI listed on the ASX in December 2015 after raising $5 million.

The company provides services in Australia and New Zealand under three categories:

- Portfolio Builder: Tools that help property investors make better purchase decisions.
- Transactions: A service that provides members with access to properties that may not be available to non-members.
- Portfolio Manager: Tools that help property investors track and account for the performance of their existing investment properties.

To view the full article, please click on the button below.

Mafematica: Could Robo-Advice Transform Pensions?

September 5th 2016, PensionsExpert.com By Louise Farrand

Would you take pensions advice from a robot? Robo-advice may be the flavour of the month, but not everyone in the pensions industry is convinced the future is fintech.

At a roundtable hosted by consultancy Barnett Waddingham, experts questioned whether a truly operational robo-advice service, which works not just in the savings phase but also at the point of and during retirement, exists anywhere in the world.

They cited several, related, concerns with the robo-advice model. The first is that robo-advice may not adequately address the needs of retirees in the complex new world of pension freedoms.

“Robo-advice on accumulation is far more straightforward, but becomes way too complex at the point of retirement and in decumulation,” says Matthew Webb, head of international benefits at Thompson Reuters.

Jonathan Watts-Lay, director of financial education provider Wealth at Work, is also sceptical.

“It’s unrealistic to rely on one financial product for 25 years. Instead, you need a service notion,” he says. “The clear trend is that people want flexibility, with the support to help them.”

And in early July, contrarian asset manager SCM Direct released a scathing report, entitled Fintech Folly: The Sense and Sensibilities of UK Robo Advice, blasting robo-advisers’ business models.

In a blog post, SCM Direct’s founder Alan Miller calls them “insane… What I have witnessed is a ‘get rich quick’ bandwagon, where wishful thinking and hype win over logic, fundamentals and business acumen”.

The report predicts that most robo-advisers will go bankrupt before acquiring the scale they need to be profitable. Merely breaking even will take nearly 11 years, the report estimates.

The same research also criticises robo-advice companies for heavily targeting millennials, whose assets make up a small proportion of the investible market, meaning robo businesses’ chances of making a profit become even slimmer.

Finally, the report argues that an online risk questionnaire cannot take into account clients’ full financial picture, nor assess other significant unconscious information (expressions, body language) they might give and is therefore unable to assess their best interests.

Bridging the gap

It may have its sceptics, but it is undeniable that robo-advice responds to a demand the pensions industry has historically failed to meet.

A 2013 report by pensions provider Aegon, The Young, Pragmatic and Penniless Generation, which surveyed consumers across Europe, found that almost a quarter of young employees (24 per cent) cite friends and family as the most important source of information in choosing how to save for retirement.

The report says: “[This] suggests that employers and professional financial services companies are either not providing appropriate support or are not providing support in a manner that is perceived to add value to these employees… it is essential that employers and retirement companies make haste in filling this gap.”

However, the majority of people are unwilling to pay for advice. The Pensions and Lifetime Savings Association’s 2014 Workplace Pensions Survey revealed that fewer than half of the consumers it surveyed (43 per cent) were prepared to pay for financial advice.

Rise of the robots

From Uber to Hargreaves Lansdown, people are turning to technology to make life easier. Why shouldn’t it play a role in bridging the advice gap, especially for people with smaller pension pots?

As Dan Egan, director of investing at US robo-advice firm Betterment, says: “If you are a young person setting out and you only have $2k-$10k to your name, no adviser will talk to you – but we are happy to.

“On the other side of things my parents are in their 70s, they use iPads, smartphones, they are very comfortable with technology. Our oldest client is 92 years old.”

A common criticism is that robo-advice is not smart enough to give savers – many of whom have nuanced finances – meaningful advice that will not lead them to seek advice elsewhere.

Unsurprisingly, it is an allegation that robo-advisers are keen to refute. Tony Vail, chief innovation officer at UK robo-advice firm Wealth Wizards, will not be drawn on numbers, but says the “majority of people can get a recommendation online”.

Similarly, Betterment’s Egan insists that “the vast majority of people get what they need on the website”.

However, both Vail and Egan are keen to emphasise that robo-advice does not have to mean “faceless”. Vail explains: “We design our online process to pick up people who may not be suited to automated advice end to end.”

Egan points out: “From the moment you sign up, you are receiving emails from real people. For example, during Brexit we had a notification in our system explaining our viewpoint to customers, with a picture of me, who is in charge of investment.

“One of the best things was the number of people who emailed me saying, ‘Thank you so much it was very useful.’ Behind every good robo-adviser are humans.”

SCM Direct’s report predicts that not all robo-advisers will survive long enough to become profit-making. However, the Betterment example from across the Atlantic illustrates just how much potential demand there could be for robo-advisers in the UK.

Egan recalls that in 2013, it had 15,000 customers and $18k (£13.7k) in assets under management, and 21 employees.

Today, it has more than 170,000 clients, slightly more than $5bn (£3.8bn) in assets under management, and 170 employees. “Our biggest problem is keeping up with growth,” he says.

Not all robo-advisers are in the same financial position, Vail adds. “The business model for many robo-advisers, where the main route to market is ‘direct to consumer’, can be challenging due to the cost of client acquisition, especially if they are trying to launch, increase awareness and build a brand and at the same time. This can create real value, but will probably rely on acquired clients consolidating assets and remaining for several years, and can require significant upfront capital.”

He notes that the dynamics may be more attractive for an established brand, such as a bank or fund management company with a large established customer base.

To view the full article, please click on the button below.

Proteomics Investigates Biomarkers for Mesothelioma

6th September 2016, ASX Announcement

  • PILL commences the search for protein biomarkers in the blood that could be used to diagnose mesothelioma.
  • World Health Organisation estimates put the cost of treatment, compensation and settlement upwards of AU$667,00 for every sufferer.
  •  Mesothelioma kills 59,000 people annually.

Perth life sciences company Proteomics International Laboratories Limited (PILL, ASX: PIQ) has begun the detailed search for proteins associated with asbestos mesothelioma.

The research aim to develop a simple blood test for the disease, which could lead to early diagnosis for some of the many thousands of currently undiagnosed people who will die from mesothelioma each year.

To view the full announcement, please click on the button below.

4Dx 2016 Retail Investment Round Fully Subscribed

4Dx Limited is pleased to announce that our initial retail offering closed on the 31st August 2016, fully subscribed.  The company has been overwhelmed with the level of interest in our world-first technology and take this opportunity to thank everyone who has expressed interest in 4Dx, and welcome all new shareholders to the 4Dx Group.

ABOUT 4DX

4Dx brings a technological solution set to disrupt this multi-billion dollar sector through compelling unique competitive advantages over existing respiratory diagnostics. The respiratory diagnostic sector represents a global market of over $25B perannum. Currently served by out of date technology, 4Dx has enormous scope for financial success as well as life changing advancement for medicine.

Offering more detailed information, faster validation of treatment efficacy, lower costs, and reduced radiation dosage, 4Dx allows for earlier detection of disease and earlier intervention.The ability to identify lung issues earlier is creating a critical shift in the practice model from cure to prevention.

Catcha Group Completes Fifth IPO

It was only 18 months ago that Catcha Group and Shaun Di Gregorio saw a huge opportunity for digital businesses in frontier markets. Together, we co-founded Frontier Digital Ventures with the goal of becoming the leading operator of online classifieds businesses in the emerging economies of the world. On Friday last week, we took one large step to realising that goal by listing Frontier on the ASX! This also marks Catcha Group’s fifth IPO! The listing is a testament to the hard work of Shaun and his team, and I’m truly excited about the tremendous opportunities for the business as it continues to grow across the globe.

This month we also welcome leading Chinese social news and content sites, Viralcham and Rojaklah to the REV Asia family. Early signs are exceptional, with tremendous growth already evident since the transition into our stewardship.

iflix also celebrated the release of its groundbreaking Playlists feature this month, showcasing the personal iflix selections and viewing habits of hundreds of celebrities and influencers across the region. I recently travelled to each market to celebrate the launch of this amazing new social feature – and knowing what’s coming with version 2.0 am super, super excited about growing our own version of social TV.

ONLINE CLASSIFIEDS PLAYER FRONTIER DIGITAL VENTURES RAISES $22.8M IN ASX LISTING

Deal Street Asia
Frontier Digital Ventures (FDV), an operator of online classified businesses in frontier markets, has successfully raised A$30 million ($22.8 million) in an oversubscribed Initial Public Offer (IPO) through the issue of 60,000,000 shares at A$0.50 per share.
Read more

CONSUMERS IN ASIA ARE MORE WILLING TO PAY FOR CONTENT AND STEAL LESS

Forbes
Consumers who were accustomed to accessing content for free – legally or otherwise – increasingly are willing to pay for it. That’s mirrored in a continuing uptick in revenues for pay TV platforms and streaming services across the region.
Read more

YOU CAN NOW FOLLOW PERSONAL PLAYLISTS OF TOP CELEBS AND INFLUENCERS ON IFLIX

Vernon Chan
iflix today launched one of its biggest new features yet – ‘Playlists’ that lets you follow personal collections of your favourite entertainment icons.
Read more

Actinogen Medical Receives R&D Tax Incentive

5th September 2016, ASX Announcement

Actinogen Medical Limited (ASX: ACW) is pleased to advise that the Company has received an R&D Tax Incentive rebate of $2,784,312 for the 2015/2016 financial year. The R&D Tax Incentive is an Australian Government program under which companies receive cash refunds for 45% of eligible expenditure on research and development.

To view the full announcement, please click on the button below.

ABOUT ACTINOGEN MEDICAL LTD

Actinogen Medical Ltd (ASX: ACW) is an Australian, publicly-listed early clinical-stage biotechnology company focused on the treatment of cognitive impairment and Alzheimer’s disease.

Actinogen is developing Xanamem™ as a novel treatment approach to Alzheimer’s disease and other age-related neurodegenerative diseases. Xanamem™ displays high potency and selectivity for inhibiting the activity of a key enzyme in the brain, which converts cortisone to cortisol. Cortisol is also known as the stress hormone, and elevated levels of cortisol has previously been linked to cognitive impairment.  The pivotal human proof of concept study, also known as XanADu, commenced in 2Q2016.

BPS Security Purchase Plan Update

2nd September 2016, ASX Announcement

BPS Technology Limited (ASX: BPS), wishes to advise that the closing date for the Security Purchase Plan 2016 (SPP) announced to the marked on 18 August 2016 will be extended from Friday, 9 September 2016 at 5.00pm.

In the last few days BPS has received an increased in the number of enquiries made with respect to the SPP and the Board has decided that given the relatively short period with which the SPP was to remain open under the original timetable to extend the SPP closing date next week.

The extension of the SPP closing date will allow eligible shareholders additional time to consider their position and provide sufficient time in which to submit their applications.

To view the full announcement, please click on the button below.

Analytica Secures Share Placement of $250,000 to Cornerstone Investor

1st September 2016, ASX Announcement

Analytica Ltd (ASX: ALT), manufacturer of the PeriCoach® System, is pleased to announce the allotment of 35,714,285 shares ($250,000) to cornerstone investor INOV8 LLC today. The shares were issued at $0.007. An appendix 3B is attached.

This is the first of two tranches, totalling $500,00 that was announced to the market 27th July 2016. The second tranche is for 35,714,286 shares and settlement is on the 30th September 2016.

These funds, together with anticipated R & D tax incentive for 2016 and the expenditure reduction program, strengthens Analytica’s cash position. Analytica continues to execute its development strategy of:

  • Building best in class,
  • Gathering evidence to show the product works,
  • Proving market acceptance, and
  • Negotiating a partnership with a corporation with the resources to commercialise across the world.

To view the full announcement, please click on the button below.

Leaf Resources Final Report & Shareholder Update

30th September 2016, ASX Announcement

The last 12 months has been a period of significant progress for Leaf Resources as we are now in an ideal  position to capitalise on the global shift away from traditional petrochemical manufacturing towards a more sustainable future.

Highlights for the year include the Claeris transaction and possible opportunities at ZeaChem’s Boardman facility, which are detailed below.

Claeris

A new era for Leaf Resources was marked with the announcement of a joint venture (JV) agreement with US-based project developer Claeris LLC in July 2016. Claeris is a world-class project developer , based in Dallas, Texas, with a track record of delivering large-scale, financially successful, renewable projects.

To view the full Report, please click on the button below.

Actinogen Medical’s Progress with Alzheimer’s Trial

1st September 2016, Actinogen

It’s been some months since our last update on Actinogen Medical and the development program for Xanamem™. Over this time we’ve made significant progress in harmonisation of the Phase II XanADu protocol and we have every expectation that all approvals for the study will be in place with the first patients recruited by the end of the year. It’s clear that through the recent interaction with the US Food & Drug Administration (FDA) we have a better, more comprehensive protocol that will provide a stronger data-set for Xanamem™ in the treatment of mild Alzheimer’s disease.

To view the full article, please click on the button below.

Long Pipes Selected to Present at Banff Venture Forum

Long Pipes Pty Ltd has been selected to present its Fluid Highway as one of 20 presenters at this year’s Banff Venture Forum, North Americas’ premier event for Investment into Sustainability.   There were a record number of applicants from around the world this year and Long Pipes is proud to have been chosen.

The Banff Venture Forum is being held this year between the 22-23 September in Banff Alberta Canada and is attended by many global; investors, energy companies and governments.

ABOUT LONG PIPES 

Long Pipes has developed, demonstrated and installed the Fluid Highway™ the “World’s first” continuous composite pipe made in the field without a joint for 1km or 1,000kms. It is the lowest cost, lightest, strongest, lowest CO2, lowest environmental impact, lowest labour and fastest to install fibre composite pipe globally.  The Fluid Highway ™ is unique it is tough, strong, flexible, designed to withstand extreme corrosion, erosion, temperature variations and pressures up to 130 Bar so far.

The Fluid Highway™ is globally unique; with strong IP, a disruptive technology in the disrupted market of fluid transportation, to replace steel, high density polyethylene and fibreglass for oil, gas, water slurry and hydro transportation. We have first contract and numerous other contracts in discussion with an addressable market of US$12-15B in the next 5 years.

Bob McKinnon Named Sprooki Chairman

6th September 2016, The Australian By David Swan

Former Westpac and Commonwealth Bank chief information officer Bob McKinnon has become chairman of ­shopper engagement start-up Sprooki as it readies itself for an ASX listing.

Mr McKinnon, who has had more than 40 years of experience in business and technology including stints as chief financial officer of MLC and Lend Lease, said Sprooki’s innovative platform instantly piqued his interest.

“I’m excited to join the board at a time when the company is well positioned for aggressive future growth,” Mr McKinnon said.

To read the article, please click on the button below.

WYZA.com.au Announces Strategic Partnership with National Seniors Australia

WYZA.com.au, Australia’s fastest growing data-driven digital marketplace targeting people 50+, today announced it had entered into a strategic partnership with National Seniors Australia.

Mike Farley, WYZA.com.au founder and CEO said the new relationship between WYZA and National Seniors kicks off in September and would immediately deliver a range of revenue generating services across travel and insurance.

National Seniors Australia was formed in 1976 and is the largest consumer lobby for older Australians with 200,000 members and representation across the country including 130 branches.

In addition to providing commercial services specifically for the over 50s cohort, it provides members and supporters with unrivalled access to policy-makers, world-class research and high quality information and publications that help over 50s navigate the second half of their lives.

Chris Grice, National Seniors Australia General Manager for Insurance & Commercial Services said that National Seniors is excited about the new partnership that will provide WYZA members with high quality products and services that the discerning over 50 customer should expect and deserve.

“This collaboration is an important endeavour in the organisation’s purpose of advancing the interests of over 50s,” said Mr Grice Mr Farley said this deep partnership with National Seniors will provide access to their back end suppliers like Allianz, Hello World and travel partners and more.

“Today Australia has over 7.9m people 50 and over and this demographic spends $4billion on goods and services each week and holds 40% of Australia’s wealth,” he said.

“There’s a growing appetite to speak directly to people 50 plus and fast-tracking access to third party suppliers will boost our ability to provide relevant commercial connections for our users while delivering new revenue sources.”

WYZA’s growth over the last year has been phenomenal with the WYZA subscriber base nearly tripling in size to 230,000 in August 16, while in the same period page views are up 314% to 1.2m, UAs up 420% to 420,000 and session duration up 14%.

To download the full announcement, please click on the link below. 

Consistent Revenue for SUDA

The revenue is consistent with the prior year and was generated by Suda Ltd’s subsidiary company Westcoast Surgical and Medical Supplies Pty Ltd. Whilst maintaining revenue, the Group has reduced operating costs resulting in a decrease in the loss attributable to members from $3.37m for FY2015 to $2.23m for FY2016.

Audit Status

This preliminary report is based on financial statements that are in the process of being audited.

Operating results

The consolidated loss of the consolidated group after providing for income tax attributable to owners of the parent entity amounted to $2,230,877 (2015: $3,367,191). The loss decreased by 34% on the loss reported for the year ended 30 June 2015. Key developments during the year are explained below.

Product pipeline and subsidiary activities

ZolpiMist oral spray for the treatment of insomnia

In December 2015, SUDA amended its cross-licence and collaboration agreement with Amherst Pharmaceuticals (Amherst), a US specialty pharmaceutical company based in New Jersey. As a result, SUDA has expanded its license to ZolpiMist™ to include all countries excluding North America. In the US market, ZolpiMist was successfully relaunched by Magna Pharmaceuticals in March 2016. SUDA is working with a multi-national contract manufacturer regarding the manufacture of ZolpiMist in their facility in Australia. The Company has also embarked on the initial steps towards registration of ZolpiMist by the Australian Therapeutics Good Administration.

To download the full results, please click on the link below.  

TFS Signs Supply Agreement With Worlds’ Leading Essential Oil Company

2nd September 2016, ASX Announcement

TFS Corporate Ltd (“TFS”, “the Company”, ASX:TFC), the world’s largest owner and manager of commercial Indian sandalwood  plantations, has today signed a five-year agreement to supply its premium Indian sandalwood oil to US-based Young Living, the largest essential oil company in the world.

Under the five-year agreement, TFS will supply Young Living with Indian sandalwood oil at US$4,500 per kg plus fixed annual increases of 2.5% per annum. The total contract value is approximately AU$50 million and the first shipment of oil is expected in October 2016 with monthly supplies thereafter.

TFS Managing Director Frank Wilson said the supply agreement further demonstrated the strong global demand for TFS’s premium sandalwood products.

To view the full announcement, please click on the button below.

YPB On Track for Step Change in Profitability

31st August 2016, ASX Announcement

  • Half year loss in line with expectations
  • Substantial progress in business development to become apparent later in H2 20216
  • A strong acceleration in revenue to commence in Q4 2016
  • Costs being judiciously controlled
  • Expectations of breakeven Q1 2017 and FY17 EBT of $5m reconfirmed

Brand Protection and Customer Engagement solutions company YPB Group Limited (ASX: YPB) is pleased to announce its financial results for the year ended 30 June 2016.

The period was pivotal for the company as it launched commercialisation of its end-to-end Anti-Counterfeit and Customer Engagement solutions suite. Significant development of the business was achieved in the half year although that progress was not yet visible in the financial results.

To view the full announcement, please click on the button below.

Significantly Accelerating MedAdvisor’s Growth Through Acquisition of Healthnotes

31st August 2016, ASX Announcement

Highlights

  • MedAdvisot today announces the acquisition of Health Enterprises 2 Pty Ltd (“Healthnotes”), a leaser in healthcare technology for medication adherence management for a total consideration of $5.5 million, paid as 60% cash and 40% scrip.
  • Compelling strategic rationale for the Healthnotes Acquisition. Bringing together the two leaders in medication adherence management. This will strengthen MedAdvisor’s strategic positioning and operational platform, offer valuable synergies and will consolidate MedAdvisor’s position as the leading Australian digital medication management company.
  • Substantially strengthens MedAdvisor’s market position and accelerates its growth strategy and path to profitability in the following ways:
    • Increases MedAdvisor’s share of connected community pharmacies to 45%, from over 1,600 to over 2,400 Australian community pharmacies;
    • Increases the number of Australian patients connected to MedAdvisor’s platforms from 220,000 to over 500,000 people;
    • Increases the number of General Practitioners (GPs) connected to MedAdvisor’s platforms to more than 4,000 GPs;
    • Extends MedAdvisor’s connected channels to over 1,700 nursing homes;
  • Increases the number and value of prescriptions ordered through MedAdvisot’s platforms to more than 320,000 prescriptions per month will be ordered with an annualised value of approximately $150 million.
  • The acquisition is expected to be earnings accretive in FY18.
  • To finance the acquisition and to provide additional working capital, MedAdvisor will raise in excess of $6 million. Peloton Capital is acting as lead advisor in the capital raise.

To view the full announcement, please click on the button below.

Big UnLimited FY 2016 Results; Preliminary Final Report; Sales Revenue Growth of 257%; Strong Member Base Growth of 125%

31st August 2016, ASX Announcement

BIG UnLimited FY 2016 Results

  • Robust sales revenue growth of 257%, reaching $2.36 million for the FY 2016 period ($0.66 million FY 2015)
  • Sales revenue predominantly driven by strong member base growth (125%) the result of successful sales initiatives and new subscription packages
  • Strong funding position and operational cash flow performance, with $3.8 million in cash as at 30 June 2016 and $4.07 million in cash receipts from customers, a 466% increase on FY 2015
  • Cash flow performance resulted in Australian operations achieving cash flow positive for March 2016 and in the final quarter (excluding corporate costs)
  • Net loss before income tax for the period totaled $7.8 million, attributable to increased expenses associated with investment in personnel, training, platform enhancement and infrastructure implementation for further overseas expansion and land grab
  • Well positioned to continue to progress growth initiatives, domestically and overseas, and customer growth expected to accelerate upon launch of enhanced platform in the December quarter
  • Enhanced platform expected to increase recurring revenue streams through subscriptions by providing customers a platform for online management of video marketing and social publishing capabilities
  • Sales pipeline continues to grow with over 18,000 members, an increase of 125% during the 12 month period

Big Un Limited (ASX: BIG, ‘BRTV’ or ‘the Company’) has today released its full year results for the year ended 30 June 2016 and is pleased to provide a review of its performance for the period.

Financial Overview

During FY 2016, the Company reported robust sales revenue of 257%, reaching $2.36 million (FY 2015 $0.66 million). This was primarily driven by video content sales in its Australian operations and a number of new products and packages, including subscription packages that were launched during the year for specific market segments. Strong sales were also a result of strong growth in the Company’s member base, a key driver of sales, which grew by 125% to 18,000 members as at 30 June 2016.

To view the full announcement, please click on the button below.

To view the Preliminary Final Report, please click on the button below.

Omni Market Tide Limited Half Yearly Financial Report; Exclusive Alliance with Boardroom Limited; Launch of Omni LOOP App

31st August 2016, ASX Anouncemennt

Review of Operations
The result for the overall operations of the Group for the six-month period to 30 June 2016 was a consolidated loss of $2,464,739 (2015: Parent loss of $325,594).
The following is a summary of the key developments in the Company’s operations during the half year ended 30 June 2016:

  • On 23 March 2016, the Company announced that it had entered into an exclusive alliance with Boardroom Limited to integrate the Company’s unique mobile stakeholder engagement applications into Boardroom’s digital solutions portfolio. Boardroom is a leading international share registry and professional services provider in the Asia Pacific region. The alliance built on an alliance between the Company and Boardroom’s Australian subsidiary entered into in September 2015.
  • On 6 April 2016 the Company launched its Omni LOOP App on both the Apple Store and the Google Play Store
  • On 30 May 2016 the Company utilised the Omni LOOP App for engagement and voting at its 2016 Annual General Meeting representing the first occasion in Australia that shareholders have been able to exercise a direct vote, attend an annual general meeting via a live stream and ask questions in real time via a mobile application.

As indicated above, the Company achieved a number of significant milestones in the development of its stakeholder engagement application during the half year. Whilst there has been considerable interest in the applications from a range of potential customers, conversion of sales leads into revenue generating contracts has been slower than anticipated. Taking these factors into consideration it was determined by the Company’s directors, in accordance with the provision of AASB138 Intangible Assets, to impair the previously capitalised intangible assets relating to capitalised developments costs resulting in an impairment charge of $520,816 being in the Consolidated Statement of Profit and Loss and Other Comprehensive Income in the half year.

To read the full Half Yearly Report and Accounts, please click on the button below.

Martin Aircraft Company Limited Consolidated Financial Statements; Director’s Report; Profit of NZ$7.6 million

31st August 2016, ASX Announcement

Director’s Report

The principal activity of Martin Aircraft Company Limited (the Company or Martin Aircraft) is the continuing development and commercialisation of the Martin Jetpack.

Director movement during the financial year was as follows:

  • Dr Luan Lin joined the Board with effect 14 August 2015
  • Dennis Chapman joined the Board with effect 2 November 2015
  • John Diddams resigned from the Board with effect from 3 March 2016
  • Jenny Morel resigned from the Board with effect from 4 March 2016

The Annual General Meeting took place on 29 October 2015. Joh Mayson, Steve Bayliss, Dr Liu Ruopeng, Dr Zhang YangYang, and Dr Luan Lun were all reappointed to the Board. Deloitte was appointed as auditor. A resolution to amend the constitution to simplify the number of Directors without reference to New Zealand as a place of residence was not passed. On 2 November 2015 Dennis Chapman, a New Zealand resident, was appointed to the Board to meet the constitutional requirements.

To view the Full Year Statutory Accounts, please click on the button below.

Tesserent Preliminary Final Report; Revenue Growth of 30.2%; Completion of Fully Subscribed IPO in February 2016

31st August 2016, ASX Announcement

Key highlights during the year

  • Revenue growth of 30.2% year on year.
  • Completion of fully subscribed initial public offering (IPO) in February 2016.
  • Successful acquisition and integration of the Blue Reef business in May 2016.
  • The appointments of Kurt Hansen as Global Head of Sales and Karen Negus as Head of Marketing further strengthens the Tesserent executive team.
  • Ongoing R&D to further enhance the services offered to our customers with an upcoming product release for our education customers expected late 2016, having been demonstrated at the recent National EduTech conference.

Commentary
Revenue for the year has increased 30.2% representing a solid position and basis to further expand. This growth rate over prior yeats (2015: 10.7$) represents the underlying growth of the Managed Security Services (MSS) business.

To view the full announcement, please click on the button below.

To download the Presentation, please click on the link below. 

Real Estate Investar Delivers Strong Year on Year Growth – Surpasses Prospectus Forecast

31st August 2016, ASX Announcement

Highlights of FY 2016 include:

  • Revenue grew by 34.4% year on year to $5.4 million;
  • Adjusted EBITDA improved from a loss of $773k in FY 2015 to a loss of $543k in FY 2016;
  • Adjusted NPAT improved from a loss of $2.1 million in FY 2015 to a loss of $1.0 million in FY 2016;
  • Real Estate Investar surpassed its 16 November 2015 Prospectus forecast for revenues, EBITDA and NPAT;
  • Membership growth was 48.0% year on year with 202.423 members as to 30 June 2016;
  • The Company completed the sale of 52 properties to members during the year with the majority completed in June 2016; and
  • The Company acquired The Property Factory and signed partnership agreements with Domain Group and one of its subsidiaries APM Pricefinder.

Real Estate Investar Group Limited (“REV Group” or “Company“) (ASX:REV), a leading provider of online services to Australian and New Zealand property investors, has released its Appendix 4E Preliminary Final Report for the 12 months ended 30 June 2016.

To view the full announcement, please click on the button below.

Analytica Announces 2016 Full Year Results; Total Revenue Up 89%; Granted US Patent for AutoStart Burette System in US

31st August 2016, ASX Announcement

Analytica Ltd (ASX: ALT) “the Company” the manufacturer of the PeriCoach system, is pleased to announce its full year results for the financial year ended 30 June 2016.

Operational Highlights

  • FDA Over-the-counter (OTC) clearance for PeriCoach
  • Granted US patent for AutoStart burette system in US
  • PeriCoach was granted patent protection in China in August
  • Received FDA clarification for sexual health indication for PeriCoach
  • AutoStart burette system listed through Queensland Health Tender in June

Financial Summary

  • Total revenue up 89% to $2.1M
  • Research & Development $2.59M
  • Marketing development $1.94M
  • Reported loss down 25% to $4.0M
  • Cash position at end of year $1.25M

In FY16 the Company completed intensive market research, and reduced sales and marketing activity which has been reflected in the reduction in spend. With capital placements this and next month, together with this year’s R&D tax credit and reduced spend, the Company has sufficient cash flow into FY17.

To view the full announcement, please click on the button below.

ThinCats Lists 2 Loans on Platform

ThinCats would like to take this opportunity to invite you to view their 2-minute video below and join the ThinCats lending community of over 370 members and a loan book of 30 secured loans aggregating $3.6m, at an average interest rate of 13.9% p.a. and an average term of 38 months.

Unlike other Peer-to-Peer or Market Place lending platforms they provide direct access to all borrower details and related financial information for loans, of course only after they have been vetted for eligibility by their experienced credit team.

ThinCats currently have 2 loans listed on the platform for $200k (@14.5% p.a.) and $220k (13% p.a) respectively. To view these and future loan opportunities, become a member. It’s simple and its free!!

Register at www.thincats.com.au , review the membership terms and conditions, download and complete an application form and once approved you will be able to transfer funds and  bids on loans.

Crowd Mobile Delivers Record FY16 Results; Revenue Up 192%; EBITDA Up 329%; Number of Countries Serviced from 25 to 54

31st August 2016, ASX Announcement

Highlights

  • Crowd Mobile delivers record financial results over 2016 financial year:
  • Revenue up 192% to $37.9m
  • EBITDA up 329% to $6.3m
  • Underlying EBITDA up 295% to $8.3m
  • Operational Cashflow up 729% to $7.0m
  • NPAT up 122% to $0.9m

Crowd Mobile revenue growth fuelled by growth across key divisions:

  • Question & Answers (Q&A): FY16 revenue up 61% to $20.7,
  • Mobile Content Subscription: FY16 revenue: $17.2 million

Crowd Mobile achieves significant growth over 2016 financial year:

  • Number of countries serviced from 25 to 54
  • Number of telco m-payments partners from 50 to 160
  • Languages covered from 12 to 30+
  • Questions answered from 5.7m to 9m
  • FY17 outlook bolstered following heavy investments made in FY16 through management time, additional infrastructure and new personnel
  • Strong foundations in place for ongoing expansion of integrated, global, mobile business positioned to deliver continued revenue growth

Wednesday, 31 August 2016 – Crowd Mobile Limited (ASX: CM8 & FWB-XETRA: CM3, Crowd Mobile, “the Company”) is pleased to announce record FY16 Financial Results and release its FY16 Presentation and Annual Report.

The FY16 period was Crowd Mobile’s first full financial year on the ASX since completing its reverse takeover of Q Limited on 13 January 2015. Over the 12 months to June 30, 2016 Crowd Mobile has achieved great success, highlighted by expansion and investment.

To view the full announcement, please click on the button below.

To view the Annual Report, please click on the button below.

To view the Results Presentation, please click on the button below.

Alcidion Group Limited Investor Update – August 2016

30th August 2016, ASX Announcement

Shareholder Update

  • Introduction to panellists.
  • Alcidion Value Proposition.
  • Achievements since listing.
  • Strategic Direction.
  • Investor Relations update.
  • Commercialisation Strategy.
  • North American Market Entry.

Alcidion Overview

  • Western Health Case Study
  • Market Opportunity
    • Global State of Health IT
    • EMR Adoption Model
  • Q&A
  • Product Overview
    • Miya Architecture.
    • Miya Parient Flow.
    • Miya Access.
    • Miya Mobile.
    • Miya ED.
    • Miya Orders.
    • Miya Clinic.

To view the full presentation, please click on the button below.

To view the Preliminary Final Report, please click on the button below.

iSentric Reports Record Results in Financial Year 2016; Group Revenue Up 13.6%; Underlying EBITDA Up 44.0%

30th August 2016, ASX Announcement

iSentric Limited (ASX:ICU) is pleased to announce its results for the 12 month ended 30 June 2016 (FY16), a period that saw the Company expand into new markets and successfully launch a number of new digital media products.

FY16 financial highlights:

  • Group revenue up 13.6% to $9.8 million
  • Underlying EBITDA up 44.0% to $2.2 million
    • Beat guidance given to the market in April 2016
    • FY15 excludes listing costs and acquisition due diligence costs as well as a loss from discontinued operations
    • FY16 excludes potential acquisition due diligence costs
  • Net Profit after Tax $1.9 million up from a loss of $0.1 million in FY15
    • A strong performance from Arte Mobile Technology Pte. Ltd. in its first full year of contribution to the Group after being acquired in February 2015 with a gross profit contribution of $2.8 million. This includes a deferred tax asset of $0.4 million being recognised as well as an over provision on tax in prior reporting period of $0.1 million
  • Earnings per share in FY16 of 1.43 cents up from loss per share of (0.02) cents in FY15

To read the full announcement, please click on the button below.

To view the Final Report, please click on the button below.

OncoSil Financial Report – Preliminary Final Report; $10m Private Placement; Advanced Manufacturing and Supply Chain Processes

30th August 2016, ASX Announcement

OncoSil Medical Ltd (ASX:OSL) (Oncosil or the Company), a late stage medical devices company focused on localised treatments with pancreatic and liver cancer, is pleased to report its financial results to the full year ended 30 June 2016 (the Financial Report) and its Appendix 4E. All financial results are in Australian dollars and are audited.

Highlights – Operational

  • The Company completed a number of milestones during the year, with the key focus being the CE Mark application in the European Union and Investigational Device Exemption (IDE) with the Food and Drug Administration (FDA) to commence the OncoPac-1 pivotal clinical study. The highlights included the following:
  • CE Mark dossier submitted to BSI and subsequently granted fast track review status
  • Submissions responding to all questions requested from BSI have been made
  • IDE application submitted to the FDA
  • Q-Submission meeting with relevant Divisional Heads at the FDA followed by IDE Amendment filing with the U.S. FDA addressing all matters raised
  • Commenced marketing efforts to introduce the OncoSil device to potential, key opinion leaders, commercial and trial centres
  • Advanced the manufacturing and supply chain processes necessary to support both regulatory filings and planned launch of the OncoPac-1 study and commercial launch
  • Completed key hires for the Company’s leadership team including Tom Milicevic, CFO; Charles Rowland, President U.S. Operations; and Michael Warrener, Sales and Marketing Director
  • Commenced a process of Board regeneration with the appointment of Dr Chris Roberts as a Non-Executive Director and Chairman-elect.

Subsequent to the year, the Company was very pleased to report the IDE approval from the EDA enabling the commencement of the OncoPac-1 Pivotal study for the treatment of patients with pancreatic cancer this year.

To read the full announcement, please click on the button below.

Aeeris Revenue Growth Over 60% & Full Year Statutory Accounts

30th June 2016, ASX Announcement 

Aeeris Limited (ASX: AER and ‘the Company’) is pleased to announce its Full Year report for the 12 months ended 30th June 2016.

Highlights

  • Total income of $1,915,547, an increase of 62% compared to $1,183,866 for the previous Full Year (30th June 2015)
  • Operating Revenues from Ordinary Activities up 49%, compared to previous corresponding Full Year
  • EBITDA (Earnings Before Interest, Depreciation & Amortisation, including write downs of intangibles) loss of ($359,377)
  • Net Accounting Loss for the Reporting Period of ($1,471,213) compared to ($722,216) for the previous corresponding Full Year
  • Net Accounting Loss includes, and is inflated by, $1,110,270 of goodwill right-downs, depreciation, amortisation and intangible impairments according to Accounting Standards
  • Net assets of 5 cents per share as at 30th June 2016, including $1.73 million cash at bank, or 3.2 cents per share

To read the full Results, please click on the button below.

To read the full Accounts, please click on the button below.

Peppermint Letter to Shareholders 2016 Annual Report

30th August 2016, ASX Announcement

Dear Shareholders,

It is with great pleasure that I provide you with an update of Peppermint Innovation’s achievements over the course of the 2016 financial year and the significant growth opportunities on the horizon.

As you would be aware, it has proven to be a defining year for the Company in terms of what we have achieved and delivered in a short time frame.

Importantly, these significant achievements have all taken place in the last 6 months of the 2016 financial year after we took control of the Company in December 2015.

We have shown the market through our announcements that we are a real business generating real revenue and having genuine partnerships in one of the world’s largest remittance markets, the Philippines, where we offer services to both the banked and the unbanked.

To read the full announcement, please click on the button below.

WYZA Nominated in CEO Magazine’s 2016 Awards

30th August 2016

CEO Magazine has revealed its finalists for the 2016 Executive of the Year Awards. Ranging over 24 categories, the awards honour and acknowledge some of the finest business leaders and professionals in Australia.

Michael Farley, CEO and founder of WYZA, is a finalist in The 2016 Executive of the Year Awards and is a contender for 2016 Start-Up Executive of the Year.

WYZA.com.au is Australia’s fastest growing digital destination for people 50 plus with over 230,000 subscribers to its weekly newsletter.

With the WYZA subscription base growing at a stunning rate – tripling in size over the last 12-15 months (59,000 in April ’15 to 151,000 in June ’16 and 230,000 in August 24, 2016), Mr Farley said that reaching 230,000 subscribers was a significant milestone for WYZA – a 100% year-on- year growth – reflecting the massive engagement of our 50-plus demographic.

To download the full article, please click on the link below. 

Alcidion to Host Investor Webinar on 31 August 2016

30th August 2016, ASX Announcement

  • Alcidion investor webinar, Wednesday, 31 August 2016
  • 10.30am Perth Times (AWST);
  • 12.00pm Adelaide/Darwin Time (ACST); and
  • 12.30pm Sydney/Melbourne/Brisbane (AEST)

Alcidion Group Limited (Alcidion or the Company) (ASX:ALC) today announced that it will hold an investor webinar on Wednesday, 31 August 2016 to discuss the results of the Preliminary Final Report, and will present the plans for the Company over the next 12 months.

To view the full announcement, please click on the button below.

Meme Capital Featured on Money Management: Why to Invest in Quantitative Funds

29th August 2016, Money Management By Jessica Amir

Investors might be missing out on attractive returns and opportunities, which a lot of brokers are unaware of, unless investors have some exposure to quantitative style funds, according to Meme Capital Management.

Meme Capital’s chief investment officer, Greg Jude, employed quantitative analysis to pick ex-ASX top 20 stocks that were going up and outperforming.

He held about 90 stocks, some of which did not have any broker research, simply because he picked stocks based on upward movements.

“We can measure those things quantitatively, as we have numbers that we assign to those things, where we compare stocks, one stock to another, a stock to an index, a stock to its peers. And therefore we automatically gravitate to those stocks that are simply doing best in the market,” he said.

He said he developed a systematic set of rules in pyramiding stock selection, based on both risk and return.

To read the full article, please click on the button below.

Proteomics Annual Report to Shareholders 2016

26th August 2016, ASX Announcement

Window On The Science – Proteins in medicine 

A revolution in medicine is well underway, underpinned by the desire for a deeper understanding of the basis of disease beyond that of classical pathology. Determining what is happening at the molecular level can guide treatment of diseases with precision. At its core, this is about proteins. The value of proteomics technology has made it a cornerstone tool to help understand the dynamics of disease in the ever-changing environment  that is the living body.

Proteins are giant, complex biological molecules that carry out all the functions within living systems. They have precise modes of action in the human body. Protein drugs, termed biopharmaceuticals, can provide highly complex functions that simple chemicals cannot perform and moreover, are less likely to cause adverse effects.

To view the full announcement, please click on the button below.

Aeeris Secures New Contracts for SecureAMS Technology

29th august 2016, ASX Announcement

Highlights

  • Aeeris has secured two important new contracts for deployment of its recently developed SecureAMS(Secure Access Management System) technology.
  • New Marketing Partnership Agreement with Australian Security Technology (AST) to jointly promote and sell theSecureAMS solution to AST customers in Australia.

Background to SecureAMS

  • SecureAMS is a unique and ground-breaking technology platform that has been developed by Aeeris in the past 12 months in response to the requirements and demands of our enterprise customers.
  • SecureAMS allows large organisations to live track, monitor and manage large workforces and external contractors undertaking activities within facilities such as casinos, shopping centres, industrial sites and infrastructure projects.

To view the full announcement, please click on the button below.

Spotlight Reporting Raises $5m

29th august 2016, NBR By Jonathan Underhill

Spotlight Reporting, which provides cloud-based tools to import data from accounting service firms such as Xero and QuickBooks to generate reports, forecasts and dashboards, says it raised $5 million from an NZVIF-backed fund, Vend’s David Wilson and Xero director Graig Winkler among others.

The Wellington-based company says chief executive and founder Richard Francis and chairman Graham Shaw, a former Xero director, also contributed to the Series A funding round.

To read the full article, please click on the button below.

Watch the QBiotics Product Overview Video


ABOUT QBIOTICS

QBiotics Limited is developing a pipeline of promising drugs in the area of cancer and wound healing. Its lead drug, EBC-46, targets solid tumours and is currently in late pre-clinical development in preparation for a Human Clinical Phase I/II trial with the USA’s FDA. EBC-46 is also in late stage development for the veterinary market through the USA’s FDA-CVM.

MedAdvisor FY16 Preliminary Results – Growth in PEP Customers, Increase of 81% in Orders Received for PEP

26th August 2016, ASX Announcement

Highlights

  • Revenue from pharmacy subscriptions and patient engagement programs (PEP) has grown by ~24% to $1.43 million, driven primarily by pharmacy subscription growth
  • Total revenue of $1.76m is 7% lower compared to FY15 which included the final licence fee payment $500,00 under the Actavis agreement
  • Gross margin from pharmacy subscriptions increased to 71%, from 43% in the prior corresponding period
  • Substantial progress reported in key operational metrics:
  • Over 180,000 patients using the platform, a 133% increase on FY15
  • Expansion of pharmacy network by 36% on FY15, to over 1,600 pharmacies
  • Growth in PEP customers, have grown to 7 manufacturers, including leading pharmaceutical companies GSK, UCB, Astra Zeneca, Novartis and Bristol Myer Squibb, with revenue uplift to be recognised largely in FY17
  • An increase of 81% in orders received for PEP compared to FY15
  • Investment made in marketing and sales teams and initiatives has strongly positioned the Company for further domestic growth and international expansion

MedAdvisor Limited (ASX: MDR, the Company), Australia’s leading digital medication adherence company, has today released its Appendix 4E and is pleased to present its maiden Preliminary Financial Report for the 12 month period ended 30 June 2016.

To read the full announcement, please click on the button below.

Peppermint Forms New Strategic Partnership with United Coconut Planters Bank

26th August 2016, ASX Announcement

Highlights

  • Peppermint and UCPB from strategic partnership wherein Peppermint will provide a proprietary platform termed ‘Peppermint Fast Remittance System’ to be installed with UCPB.
  • The Peppermint Fast Remittance System will be used by customers, such as Money Transfer Operators and Remittance Companies in processing international remittances to beneficiaries in the Philippines.
  • Services offered via the Peppermint Fast Remittance System will utilise the Interbank Funds Transfer (IBFT) facility in the Philippines.

PERTH, AUSTRALIA, 26 AUGUST 2016: Peppermint Innovation Limited (ASX: PIL) (“Peppermint” or “the Company”) is pleased to advise United Coconut Planters Bank of the Philippines (“UCPB”), an established and respected top tier bank in the Philippines, has entered into a strategic partnership with Peppermint to install the Peppermint Fast Remittance System, a proprietary remittance platform designed by the Company.

The installation of the Peppermint Fast Remittance System with UCPB will facilitate international remittance services using the Interbank Funds Transfer (IBFT) facility in the Philippines.

UCPB is currently using Peppermint’s platform to offer mobile banking and payment services to its account holders.

To read the full announcement, please click on the button below.

Altech Chemicals Ltd Receives Speculative Buy from Perth Broker

25th August 2016, Proactive Investors

Altech Chemicals Ltd (ASX:ATC) has received a Speculative Buy from Perth-based stockbroking firm DJ Carmichael.

The broker applied a valuation of $0.355 from $0.41 per share. The following is an extract from the report.

ECA financing steps in final throws

ATC are making good progress on their project funding application to the Federal Republic of Germany’s Export Credit Agency (ECA).

ATC are now at stage 7 of a 9 stage process that, if successful, will result in the majority of the project debt being provided at an extremely low interest rate.

In addition, ATC is seeking to increase the percentage of total project debt to be covered under export credit, thereby decreasing the repayments and increasing yearly project cash flows.

The recent successful $10m capital raise should see ATC funded through to first drawdown of the project funding Q1 CY17.

To read the full article, please click on the button below.

TFS Strong FY16 Established Platform for Transformational FY17

26th August 2016, ASX Announcement

Highlights

  • Cash EBITDA of $62.2m (FY15: $57.5m), up 8.2% on prior year and in line with guidance
  • Over 1,600ha of new plantations established in FY16, ahead of guidance
  • Completion of the third annual harvest, with more than 32,000 trees harvested – on track to deliver over 300 tonnes of heartwood, a tenfold increase on the 2015 harvest
  • Long-term contracts secured with Chinese and Indian wood buyers
  • Supply agreements now in place for the majority of harvests through to 2021
  • Strong financial platform established for further growth, with cash balance of $107.0 million (30 June 2015: $72.7 million) and debt refinance completed
  • Transformational harvest to drive at least a 25% increase in Adjusted Cash EBITDA in FY17

TFS Corporation Ltd (“TFS”, “the Company”, ASX:TFC), the world’s largest owner and manager of commercial Indian sandalwood plantations, has recorded Cash EBITDA of $62.2 million for the twelve months ended 30 June 2016, up 8.2% on FY15 and in line with guidance.

Cash revenue increased 16.1% to $175.5 million (FY15: $151.2 million), driven by increases in plantation establishment fees, sandalwood product sales, and management fee income.

Reported Net Profit After Tax was $90.1 million, down 20.3% on FY15 ($113.0 million), due mainly to a reduction in non-cash revenue that was driven by a lower net unrealised foreign currency gain on $19.0 million compared to the prior year (FY15: $55.7 million).

To read the full announcement, please click on the button below.

To view the Full Year Results Presentation, please click on the button below.

STARIN’s Adina Apartment Hotel to be Built in Macquarie Park, North Ryde

9th August 2016

154 Room Hotel to Open in Sydney’s Rapidly Growing Business District

TFE Hotels will operate a stunning new Adina Apartment Hotel in Sydney’s second biggest and fastest growing buiness and commercial district, Macquarie Park at North Ryde, for owner STARIN, a Sydney-based boutique fund manager that actively engages in prime commercial property of hotels and serviced apartments. The new Adina Apartment Hotel is STARIN’s flagship project and it will deliver design excellence and commercial retuns, fulfilling the high demand for accommodation from businesses in Macquarie Part, by being the first and tallest fully serviced apartment hotel.

STARIN’s Adina Apartment Hotel Macquarie Park designed by Group GSA, will offer sweeping views of Sydney’s city skyline from its 19 storeys and includes and infinity pool, gym and bar on the top floor. It will comprise 154 hotel apartments, a ground floor reception, cafe and bar with an outdoor area and conferencing. Construction is starting now with planned completion end of 2017.

To read the full media release, please download the file below.

MedAdvisor Launching New Feature in Collaboration with Diabetes Australia

25th August 2016, ASX Announcement

Melbourne, 25 August 2016: MedAdvisor Limited (ASX:MDR) Australia’s leading digital medication adherence company, in collaboration with the national diabetes organisation Diabetes Australia, today launches a new tool that allows people living with diabetes to order their consumable products and ensure accurate supply in pharmacy.

Under the National Diabetes Services Scheme (NDSS) – funded by the Australian Government and administeres by Diabetes Australia all NDSS subsidised diabetes consumable products, such as blood glucose testing strips, insulin pen needles and insulin pump consumables, are now only available through pharmacies. Previously, people living with diabetes were able to order their supplies online.

In anticipation of this significant change, MedAdvisor has developed and now launched customised features which will enable people with diabetes and their carers to reserve NDSS products remotely for collection from their MedAdvisor Network Pharmacy of choice. People with diabetes and carers will also be able to track their usage and supply for NDSS products and reorder these items through their MedAdvisor App or through MedAdvisor on their desktop computer.

To read the full announcement, please click on the button below.

Folkestone’s Full Year Results – Normalised Net Profit after Tax up 71.2%; Annual Report; Results Presentation; Investor Review

25th August 2016, ASX Announcement

Folkestone’s Full Year Results – 30 June 2016

  • Normalised net profit after tax of $5.0 million, up 71.2% on FY15
  • Normalised earnings per share of 3.4 cps, up 49.3%
  • Net asset value (NAV) per share of 98.9, up 13.1%
  • Gearing reduced to 4.2%, down from 15.6%
  • Funds under management of $1.05 billion, up 14.7%
  • All funds outperformed their relevant investment benchmark
  • $16.9 million unrealised gain ($11.8 million net of tax) generated from FLK’s co-investment in Folkestone Education Trust (ASX: FET)
  • Strong sales across active development projects
  • Added three new development projects to the pipeline
  • Established FLK’s Seniors Living platform
  • FLK to pay a fully franked dividend of 2.5 cps – the first dividend in 8 years

Financial Results

Folkestone (ASX: FLK) today announced a normalised net profit after tax for the 12 months ended 30 June 2016 of $5.0 million, an increase of 71.2 per cent over FY15. Statutory net profit after tax was $5.5 million, down 22.3 per cent over FY15.

Normalised earnings per share is 3.4 cents compared to 2.3 cents for FY15. Statutory earnings per share is 3.7 cents compared to 5.5 cents for FY15.

Folkestone’s Managing Directon Mr Greg Paramor said “the solid result for FY16 reflects positive contributions from both our funds management platform and our on-balance sheet development activities. It also reflects our focused and disciplined approach to implementing our strategy in an environment where capital is abundant and competition for assets is driving prices close to cyclical highs in many sectors”.

To read the full announcement, please click on the button below.

To view the Investor Review, please click on the button below.

To view the Investor presentation, please click on the button below.

To view the Annual Report, please click on the button below.

Altech Updated Research Report

25th August 2016, ASX Announcement

Altech Chemicals Limited (Altech/ the Company) (ASX: ATC) is pleased to advice of the release of an updated research report titled “ECA financing steps in final throws” by Perth-based stockbroking firm DJ Carmichael. Written by DJ Carmichael Head of Research, Mr Paul Adams, the report is follow-up from Mr Adams’ initial research report on the Company published in February this year (refer ASX announcement dated 26 February 2016).

A copy of the updated research report is now available on the Company’s website: www.altechchemicals.com.

To read the full announcement, please click on the button below.

Booodl featured in the Deloitte Retail Trends Report Vol. 1

It’s the Booodl mission to help physical retail thrive by driving shopper visits and sales for stores, brands, malls and high streets. Given that, we’re thrilled to have Booodl included in the latest Deloitte Retail trends report released yesterday.

The paper is the first in a series looking at the Australian retail sector and how retailers can adopt new technologies and better engage customers. Booodl, being one of those technologies, is featured alongside others (Myagi, Oak Labs, Fluent Retail, With.Me) looking to improve the physical store discovery and in-store experience.

Read our blog post on the report or download the full report via the Deloitte website. We’d also really appreciate if you could help amplify the report through your own networks. A couple suggestions to get the ball rolling:

  • Great to see @booodl featured in the Deloitte #RetailTrends report goo.gl/W6Upj8 #StoreDiscoveryOptimisation
  • Vol. 1 of Deloitte’s #RetailTrends report is out & @booodl is in for their work helping retailers get discovered goo.gl/W6Upj8

LatAm Autos Delivers Record Revenue Growth of 44.7%

23rd August 2016, ASX Announcement

Leading Latin American online auto classifieds business LatAm Autos Limited (ASX:LAA), is pleased to announce its results for the six months ended 30 June 2016 (1H 2016).

Commenting on the Company’s growth over the first half of 2016, Executive Chairman Mr Tim Handley said: “We have a focused growth strategy in place with the aim of making LatAm Autos the dominant dedicated online auto classified and content company in Latin America [excluding Brazil]. The first half results, financial and operationally, have delivered to our expectations.”

“We have continued to successfully grow market share and our products have gained strong traction, as can be seen in LatAm Autos’ revenue growth in local currencies of between 24% and 70% in each of the markets we operate in. In addition, with 186,000 listings, more dealers and higher site traffic, we are well placed to continue our growth trajectory over the second half of this year and move closer to cash flow break-even,” added Mr Handley.

1H 2016: Investing in growth

  • Revenue up 44.7% to $3.9 million (vs 1H 2015)
  • Underlying EBITDA loss of $6.0 million
  • Cash of $12.7 million at 30 June 2016

To find out more about LatAm Autos, please click on the button below.

To read the full announcement, please click on the button below.

To view the Results Investor Presentation, please click on the button below.

Aurora Labs Share Price Soars Since Listing Last Week

22nd August 2016, AFR by Trevor Sykes

Float of the Week

To Aurora Labs (A3D) whose 20¢ shares were listed on August 16 and by August 18 had soared to 90¢. The company raised $2.8 million to pursue innovative proprietary technologies for 3D metal printing.

Three-dimensional printing? According to the prospectus, a 3D image is processed into digital slices, which are fed sequentially into a printer. Then lasers lay down layers of print corresponding to the images received.

It all sounds highly fictional to me, but the punters must believe it because in two days of listing A3D was a four-bagger.

To read the full article, please click on the button below.

Perth Startup Aurora Labs Goes Public after Raising $2.8 million

18th August 2016, Startup Smart by Denham Sadler

Perth-based 3D printing startup Aurora Labs is officially a public company, listing on the ASX on Tuesday morning after successfully raising $2.8 million through an IPO.

Aurora Labs develops a range of metal 3D printers that it says are far cheaper than its competitors.

The startup offered 14 million shares at 20 cents each to raise the $2.8 million after lodging a prospectus in June.

Aurora Labs opened its first day of trading at 54 cents and closed on Wednesday at 70 cents.

Aurora Labs CEO David Budge says it’s an “exciting” moment for the early-stage tech company.

“The whole process of moving from private to public is a fairly steep learning curve for anybody,” Budge tells StartupSmart.

“It’s been a very good process overall and we’re certainly very happy with the results in the end.

“There’s a lot of interest in the company moving forward and this is a fairly significant milestone. We’re only two years old and this is a big stepping stone.”

The cash injection from the listing will be used to bring Aurora Labs’ small format 3D printer to market and further the development of the medium and large models, Budge says.

“The idea behind it is to take the technology we’ve developed with the small format printer and get it into the marketplace,” he says.

“We’ve reached the end of the beta testing phase and we’re moving into production.”

He says he originally set out to raise a round of private funding to facilitate this but after encountering difficulties decided to turn to the public markets.

“We examined the private route extensively and that was our preferred method originally,” Budge says.

“We found it difficult to get funding in Australia. If we had been in the US we would’ve found it somewhat easier but we were keen to keep it as an Australia company so we decided on IPO funding for the next level.”

To read the full article, please click on the button below.

YPB First Commercial Contract in Mexico

24th August 2016, ASX Announcement

Brand Protection and Customer Engagement solutions company YPB Group Limited (ASX: YPB) has secured its first commercial contract in Mexico through its joint venture (JV) with Affyrmx Group.

The initial contract value is US$130,000, with YPB’s proprietary tracer solution to be used to PROTECT redeemable food coupons that are frequently the subject of counterfeit. The end client is actively engaged in programs supporting people in need.

Earlier this year YPB entered a JV with Affyrmx with an initial focus on Government Vital Documents in Mexico. To date YPB has received contracts to supply Vital Records to four Mexican states, with outstanding opportunities across all of the country’s 32 states, governing a population of more than 120 million.

While continuing to develop opportunities in the government sector Affyrmx is now actively pursuing deals in the commercial sector with YPB.

To read the full announcement, please click on the button below.

Craig Farrow Joins Bulletproof Board

24th August 2016, ASX Announcement

Bulletproof Group Limited (ASX:BPF) welcomes Craig Farrow to the board as a non-executive director, effective today. Mr. Farrow has also accepted the role as chair of the Audit and Risk Committee.

Mr. Farrow is a Fellow of Chartered Accountants Australia New Zealand (CAANZ), Australian Institute of Company Directors (AICD) and Australian Institute of Management (AIM), whilst also a certified participating manager and holds a Diploma of Financial Services. A founding Partner of Brentnalls SA, he is now Chairman and continues as a partner of that firm.

Mr. Farrow is currently the deputy chairman of Vocus Communications, following its merger with M2 Group, where he held the Chairman role since 2006, having been part of the founding team of M2 in 1999. He is also a director of a number of private and unlisted public companies in the agribusiness, technology and professional services sectors.

To read the full announcement, please click on the button below.

Proteomics International Expands Diagnostics Portfolio to Endometriosis

24th August 2016, ASX Announcement

Life sciences company Proteomics International Laboratories Ltd (PILL, ASX: PIQ) is applying its disruptive proteomics technology platform to new areas of significant unmet medical need.

  • PILL is investigating protein ‘fingerprints’ that can diagnose endometriosis from a simple blood test.
  • Endometriosis affects one in ten women in their reproductive years and costs Australia $7.7 billion annually.
  • The research employs PILL’s proven Promarker platform, which has already been used to develop a predictive test for diabetic kidney disease, and could deliver results within 12 months.

Perth company PILL is investigating proteins in the blood that are associated with endometriosis, paving the way for the development of a quick and easy diagnostic test for the painful condition.

Endometriosis occurs when the tissues that line the uterus spread and surround other organs. The condition affects one in ten women in their reproductive years (15-49) and costs $12,000 per year for every person diagnosed – both incidence and health burden are comparable with diabetes.

To view the full announcement, please click on the button below.

Bulletproof Delivers Record Growth: Revenues Up 69%; Full Year Presentation; Full Year Financial Report

24th August 2016, ASX Announcement

SYDNEY, Australia – Bulletproof Group Ltd (ASX: BPF) is pleased to announce its results for the 12 months ended 30 June 2016 (FY16) that saw the Company deliver record growth in revenue and solid profit performance.

FY16 Results

  • Full year revenues $47.2m, up 69% on FY15, 31% organic growth
  • Underlying EBITDA $4.7m, up 13% on FY15
  • Underlying EBIT $0.9m, up 2% on FY15
  • Underlying NPAT $0.8m, up 51% on FY15
  • Operating cash flow $5.1m, up 49% on FY15

Highlights

  • Successful integration of professional services acquisition, providing strong revenue growth
  • Completed acquisitions of Infoplex and Cloud House
  • Successful deployment of Sell Anywhere product with major retailer
  • Significant new blue chip customer wins, with over 750 customers now in the portfolio

Commenting on the FY16 results, Bulletproof Group’s CEO Anthony Woodward said:

“We are pleased to have been able to deliver another year of strong organic growth. When combined with our acquisitions, it has been a record year for overall revenue growth, which was up 69 per cent to $47.2 million, as a result. This reaffirms that our strategy is delivering responsible growth, product superiority and service excellence from a commanding, market-leading position.”

To view the full announcement, please click on the button below.

To view the Full Year Presentation, please click on the button below.

To view the Financial Report, please click on the button below.

Altech Receives Loan Indicative Terms and Conditions

24th August 2016, ASX Announcement

Highlights

  • Altech receives lenders first draft indicative term sheet
  • Altech targeting total project debt of US$70 million
  • Export credit cover (ECA) component of US$60 million
  • Sole lender structure proposed for the entire debt portion of up to US$70 million
  • Simplified debt financing and attractive ECA-covered component

Altech Chemicals Limited (Altech/the Company) (ASX: ATC) is pleased to announce that the Company has received a summary of senior facility agreement indicative terms and conditions from German government-owned KfW IPEX-Bank for the proposed US$70 million of debt financing of its Malaysian high purity alumina (HPA) project.

The indicative terms and conditions proposed by KfW IPEX-Bank includes matters customary for the type of project debt financing being targeted, such as description of credit facilities; interest rates and fees; debt payment terms and maturity dates; collateral security; affirmative and negative covenants; details of guarantors; closing conditions; financial covenants; representations and warranties; events of default and material adverse changes. The details for these matters and potential adjustments are currently under discussion and will take into account the results from the ongoing due diligence process where necessary, before being submitted for approval within the German export credit agency and KfW IPEX-Bank.

To view the full announcement, please click on the button below.

QBiotics Share Offer Update: View Investor Presentation Online; Share Offer Progress; Seven News Story; Frequently Asked Questions Answered

QBIOTICS SHARE OFFER UPDATE
The QBiotics Share Offer has now been open for 1 week. Below is an update on how it is progressing, as well as links to further useful information and FAQs about the Offer.

UPDATE ON SHARE OFFER PROGRESS
The QBiotics Share Offer opened on Monday 15th August and has been very well received. It is already over 50% subscribed and we expect it will close in the coming weeks. Should the Offer close early, we will inform you in advance.

If you intend to apply for shares in this Offer, and have not done so already, we encourage you to do so ASAP. You can apply for shares via the Share Offer site www.qbiotics.com/prospectus.

Shares are $0.40 and the minimum investment is $5,000 (12,500 shares).

INVESTOR PRESENTATION VIDEO AVAILABLE TO VIEW ONLINE
Given that some investors could not attend the recent Investor Roadshow Presentations, we recorded it and it is now available to view. Please click below to view this video.

SEVEN NEWS STORY ON EBC-46
On Monday 15th Aug, Seven National News ran an exclusive story on the human trial results of EBC-46. It was watched by over 1.9m people. If you missed the story, you can watch it below.

The Cairns Post also ran a story on QBiotics yesterday. You can view it HERE.

There is more media planned for QBiotics in the coming weeks. As the stories are published we will upload them to the QBiotics Offer site under the Media section.

PRINTED COPY OF PROSPETUS
A printed copy of the Prospectus was posted to all QBiotics shareholders yesterday. If you are not an existing QBiotics shareholder and would like a printed copy, please email info@axstra.com.au and include your name, mailing address and phone number. We will post it to you free of charge.

FREQUENTLY ASKED QUESTIONS
Since the Offer opened, we have received many questions about the Share Offer and the Application process. Below are some of the most frequently asked questions, along with answers:

QUESTION ANSWER
Which online Application Form do I use? If you are an existing QBiotics shareholder, use the Priority/Existing Shareholder application button, located on the right side of the Offer website. Enter your Entitlement Number and details to apply. Shareholders were emailed their unique Entitlement Numbers on Monday 15th Aug. If you did not receive your Entitlement number, or have lost it, please email info@axstra.com.au to request it.If you are not an existing shareholder, please use the General application button.
If I pre-registered, but am not a QBiotics shareholder, will my application still be prioritised? If you pre-registered for the Share Offer, but are not an existing shareholder, you must use the General Offer to apply for shares. However should the Offer be oversubscribed, your application will still be prioritised over those who did not pre-register. The Offer Manager holds the list of everyone who pre-registered and this will be cross checked when the Offer closes.
If I’m an existing shareholder, can I apply for shares under a different entity? Yes, you can. To apply for Share under a different entity to your existing shareholding in QBiotics, simply use the General Offer button on the Share Offer site. Once you have completed the application, email reuben@axstra.com.au and notify him that you are an existing shareholder, and that you have applied for shares as a different applicant. Reuben will mark your new application as an existing shareholder and you will be prioritised in the Share Offer.
Do I have to use BPay to pay for Shares? Yes. If applying via the Offer Site, the only way to pay for Shares is via BPay. By using BPay your unique BPay code is matched with your application. There is no option to transfer funds via EFT or any other means. If this is a problem, please contact Offer Manager Reuben Buchanan on reuben@axstra.com.au to discuss options.
If I’m an overseas investor, can I apply in the QBiotics Share Offer? Due to Australian laws related to capital raising, only Australian residents can apply for shares in the QBiotics Share Offer under the current Prospectus.
When will the Offer close? The Offer is scheduled to close on the 9th September. However, if the Offer is fully subscribed prior to the 9th of September the Offer may close early. If it is likely to close early, we will notify all applicants, shareholders and those who preregistered in advance.

PRINTED APPLICATIONS
Although we encourage all investors to apply for shares via the Share Offer site, it is possible to apply using a physical Application Form contained in the Prospectus. If you wish to apply for Shares this way, please do so ASAP and mail the Application Form, along with a cheque as per the instructions contained on the Application form.

CONTACT
Once again if you have any enquiries or need help with anything relating to this Share Offer, please contact Offer Manager Reuben Buchanan at reuben@axstra.com.au.

Anti-Cancer Drug Discovered in Rainforest Successfully Tested on Humans

22nd August 2016, The Cairns Post by Daniel Bateman

A POTENTIAL cancer cure discovered in Far North Queensland that has been successfully tested on human patients is hoped to become commercially available in four years.

Brisbane-based researchers QBiotics have released the ­results of their first clinical trials of the drug EBC-46.

The drug has been derived from the seeds of the rainforest blushwood tree, which grows on the Tablelands.

Eight cancer patients across Australia were tested with the drug, which successfully treated four different types of ­tumours that included melanoma, squamous cell carcinoma, basal cell carcinoma, and breast adenocarcinoma.

QBiotics CEO Dr Victoria Gordon said none of the ­patients, who were treated at hospitals in Brisbane, Sydney, Melbourne and Adelaide, showed any negative side ­effects from the drug.

“Our last patient – which was our melanoma patient – we had total tumour destruction in both of the tumours that we treated,” she said.

“We’re very happy about that.

“Within seven days, the ­tumours were gone.

“The exciting thing is the drugs are responding in exactly the same way in tumours in cats and dogs and horses.

“It’s proving our theory that it’s not species-specific, and it’s not tumour-specific either, ­because it’s actually working in a range of tumours.”

To read the full article, please click on the button below.

Kordia and Thinxtra Internet of Things Network Passes Halfway Mark

22nd August 2016, Scoop Media

Business-focused service provider Kordia together with partner Thinxtra, says the deployment of a dedicated new Internet of Things (IoT) network, being established nationwide, has officially passed the halfway mark.

The opening of a major new site in Hamilton last week pushed the outdoor coverage of the network to 50 per cent of New Zealand’s population.

The network also racked up an unofficial world record for the greatest distance over which data has transmitted on a SIGFOX IoT network to date, with data sent 212 kilometres between a Kordia site in North Canterbury and another in Wellington.

“The transmission surpassed a previous distance record of 195 kilometres, which occurred between the Pyrenean Mountains and Toulouse in France”, says Aaron Olphert, Kordia’s CTO.

Darren Robinson, who heads global sales and marketing at cornerstone investor Rakon, says the go-live of Hamilton is a significant milestone which further validates the Kiwi tech company’s decision to invest with Thinxtra.

“The Hamilton site ensures comprehensive coverage for the Golden Triangle region of Auckland, Waikato and the Bay of Plenty,” says Robinson.

“This area is home to some of New Zealand’s most important primary producers, as well as the country’s most important logistics hubs.

“The IoT has the potential to revolutionise these industries and turbocharge the contribution they make to New Zealand’s economy, and we are delighted to play our part in realising that potential.”

To read the full article, please click on the button below.

Charter Hall Achieves 29% FUM Growth to $17.5 billion; Annual Results Presentation; Full Year Financial Report

22nd August 2016, ASX Announcement

Charter Hall Group (ASX:CHC) (Charter Hall or the Group) today announced its full year results for the 12 months to 30 June 2016. Key financial and operational highlights for the period are:

Financial highlights:

  • Statutory profit after tax of $215.2 million, up $97.3 million
  • Operating earnings of $124.7 million, up 26.2%
  • Operating earnings per security of 30.4 cents, up 10.5%
  • Distribution per security of 26.9 cents, up 11.2%
  • Net Tangible Assets per security of $3.04, up 10.1%

Operational performance:

  • Access: Gross equity inflows of $1.5 billion from diversified equity sources.
  • Deploy: Completed $3.7 billion of property transactions. $3.0 billion in acquisitions, $0.7 billion in non-core divestments.
  • Manage: 29% growth in funds under management (FUM) to $17.5 billion. Completed 545 leasing transactions.
  • Invest: Net $56 million invested alongside our capital partners. 6.46% WACR and 7.9% discount rate. Property Investment earnings growth of 26.4%.

Charter Hall’s Group CEO and Managing Director, David Harrison said: “Growth of 29% in FUM to $17.5 billion and 10.5% OEPS growth reflects the Group’s strategy focusing on accessing, deploying, managing and investing capital.”

To view the full announcement, please click on the button below.

To view the Annual Results Presentation, please click on the button below.

To view the Full Year Financial Report, please click on the button below.

Placer Property Investor Newsletter

Placer Property has launched The Stables Property Fund. The development of the Centre was managed by Placer Property and was opened in April 2015.

The Stables Shopping Centre is a new 5,605 square metre convenience based, neighbourhood shopping centre anchored by a large format Woolworths Supermarket and BWS liquor outlet. The Stables also accommodates a range of specialty tenants including cafes, a hairdresser and take away food outlets, as well as offering parking for 260 car directly in front of the centre.

The Stables Shopping Centre is located in Golden Grove, approximately 22 kilometres northeast of the Adelaide CBD. It is located on a highly visible corner site at the intersection of Golden Grove Road and Crouch Road in an affluent trade area.

Key features of the Fund include:

  • 7.60% Forecast Yield in FY16 and FY17
  • Woolworths as anchor tenant
  • WALE of 11 Years by rental income
  • High initial forecast $0.95 Net Tangible Asset per Unit

Oncosil Medical Investor Presentation August 2016

22nd August 2016, ASX Announcement

Overview

  • Developing an implantable radiotherapy medical device ‘OncosilTM’ for pancreatic and liver cancer
  • CE Mark targeted in the near term followed by commercial launch and sales in UK, EU and Australia
  • Technology platform suitable for multiple solid state tumours providing a more targeted therapy
  • Global pancreatic cancer market > US1$B
  • Global Pivotal Study underway – FDA approved IDE – July, 2016 Trial sites being engaged
  • New leadership team – Daniel Kenny CEO (ex Baxter, Roche) and Dr Chris Roberts (ex Cochlear CEO) Chairman-elect
  • Proprietary technology with robust patient portfolio
  • ASX listed ~ $69m market cap and $13.4m of cash

Device Overview: Radiation therapy delivered directly into the tumour

  • Pure “soft beta” radiation source (P32) to avoid systemic side effects
  • Localised radiation therapy using “sticky” microparticles
  • Carrier particles are inert silicon
  • Particles are suspended in fluid to allow direct injection into the tumour
  • Single Injection under anesthesia takes 30 minutes
  • Local radiation in the tumour lasts around 3 months

To view the full Presentation, please click on the button below.

Crowd Mobile to Raise $3 Million Via Placement & Rights Issue

19th August 2016, ASX Announcement

Highlights:

  • A$2.4 million raised through a share placement
  • A$1.0 million Rights Issue which is partially underwritten
  • Funds raised will support our ongoing marketing initiatives, investments in product development and earnings growth strategy.

Crowd Mobile Limited (ASX:CM8 & FWB-XETRA:CM3, Crowd Mobile, “the Company”) is pleased to announce that it has received commitments from sophisticated and professional investors to subscribe for A$2.4 million of new and  fully paid ordinary shares in the Company at 16 cents per share with a 1 for 2 free attaching option exercisable  at 27 cents, expiring 2 year from the date issue (“Share Placement”).

Crowd Mobile also announces a Non-Renounceable Rights Issue to raise A$1.0 million on the same terms as those of the Share Placement (“Rights Issue”). A$0.6 of the Rights Issue is being underwritten by DJ Carmichael Pty Limited (“DJC”), which combined with the Share Placement raises A$3.0 million in total.

To view the full announcement, please click on the button below.

BPS Delivers Record FY16 Results & Security Purchase Plan

18th August 2016, ASX Announcement

Highlights:

  • Robust business development drives record revenue of more than $50 million
  • Investment in bolstered salesforce drives EBITDA of $9.5 million
  • Transformational acquisition of Entertainment to boost FY17 revenue by 118% and drive projected EBITDA growth of 49% in current year
  • Final dividend of 2.0 cents per share taking full-year dividends to 4.0 cents per share

Leading channel enablement and payments platform provider BPS Technology Limited (“BPS”, “BPS Technology” or “the Company”) is pleased to release full year results for the year ending 30 June 2016 (FY16).

In its second year of operation since listing on the ASX in September 2014 the Board set some ambitious goals for BPS 2016.

To view the full results, please click on the button below.

To view the Share Purchase Plan, please click on the button below.

Instituional Investment Survey Meme Again Beats Top Performing Funds

An article in today’s Money Management newsletter reported on the results of a recent Institutional Sector Survey which listed the top performing Australian Equity funds (on the basis of their before fee returns) for the year to the end of July 2016. As a boutique fund the Meme Australian Share Fund’s current assets under management of $5.8 million are below the threshold for inclusion in these results, however the chart below shows how our Fund fared over the same period when compared (on an after fee basis) to the quoted current leaders (data sourced from FE Analytics).

 

 The Meme Australian Share Fund invests in listed Australian equities outside the ASX20 and takes an evidence-based quantitative approach to investing.  The Fund employs a robust and back-tested trend-following strategy to identify investment opportunities expected to provide both positive price appreciation and relative price out-performance over the medium to long term while maintaining a strict risk-management regime to limit losses in any market downturn. The Fund remains open to new investment.

Hot Calibration Run of the OncoSil Device

18th August 2016, ASX Announcement

OncoSil Medical Limited (ASX: OSL) (OncoSil Medical or the Company), a late stage medical device company focused on localised treatments for patients with pancreatic and liver cancer, is pleased to announce that it has successfully completed a supply chain validation process including the first hot (radioactive) calibration delivery of OncoSil™.

In preparation for the commencement of the Company’s planned global clinical study of OncoSil™ for the treatment of pancreatic cancer (Oncopac-1) and the commercialisation of OncoSil™ subject to attainment of CE Mark, the Company restarted de-novo manufacturing of OncoSil™ microparticles in January 2016. The manufacturing, supply chain validation and delivery to clinical and commercial centres of OncoSil™ product is a key step to commercial sales and the treatment of patients in the OncoPac-1 Study.

To view the full announcement, please click on the button below.

Proteomics Secures First Commercialisation Deal for PromarkerD

18th August 2016, ASX Announcement

Life sciences company Proteomics International Laboratories  (ASX: PIQ) (PILL) has signed an exclusive license for its PromarkerD assay for the diagnosis of diabetic kidney disease in the Dominican Republic in Central America.

Highlights:

  • Diabetic kidney disease test to be commercialised in the Dominican Republic in a deal worth in excess of USD 1.5 million.
  • The agreement marks the first international licensing deal for the PromarkerD assay.
  • Manufacturing will occur in US Territory of Puerto Rico and the deal paves the way for other markets including the United States, China and Japan.

The licence granted to Omics Global Solution (Omics) for the Dominican Republic for the PromarkerD assay will provide significant economic benefit to PILL. Although the Dominican Republic has only 10.6 million people, the net present value of financial terms in excess of USD 1.5M for the first nine years of the agreement.

To view the full announcement, please click on the button below.

YPB Signs Contract With Major Beijing Museum

17th Augus 2016, ASX Announcement

  • YPB to sell invisible anti-counterfeit tracer technology to newly developed Art Museum in Beijing

Brand Protection and Customer Engagement solutions company YPB Group Limited (ASX: YPB) has signed a contract with a leading art museum in Beijing to PROTECT it with YPB’s anti-counterfeit tracer technology.

YPB’s invisible tracer will be applied to the museum’s entrance tickets, with YPB’s scanner technology being used to authenticate tickets at the point of entrance.

The contract is expected to deliver approximately A$200,000 revenue to YPB in the first year.

To view the full announcement, please click on the button below.

Altech Targets US$70m Project Debt for Malaysian HPA Plant

17th August 2016, ASX Announcement

Highlights:

  • Altech targeting total project debt of US$70 million
  • Export credit cover (ECA) component increased to US$60 million
  • Residual debt component now up to US$10 million
  • Sole lender structure proposed for the entire debt portion of up to US$70 million
  • Simplified debt financing and attractive ECA-covered component

Altech Chemicals Limited (Altech/the Company) (ASX: ATC) is pleased to announce that the Company’s targeted debt financing for its proposed Malaysian high purity alumina (HPA) project has increased to US$70 million (previously $60 million).

The export credit cover (ECA) component to be covered by the German export credit agency (ECA), Euler Hereme Aktiengesellschaft (Euler Hermes) has increased from US$40 million to US$60 million.

To view the full announcement, please click on the button below.

Actinogen Receives Offer to Purchase All Less Than Marketable Parcels of Shares

16th August 2016, ASX Announcement

The Board of Actinogen Medical Limited (ASX: ACW) (Actinogen or the Company) is pleased to announce that it has received an offer from an Australian financial services licensee to purchase all less than marketable parcels of shares in the Company for $0.0645 per share (Offer).

A less than “marketable parcel” (defined in the ASX  Listing Rules as a parcel of shares with a market value of less than $500) will be any shareholding of 8,928 shares or less (Less than Marketable Parcel) on the record date. The record date for the purpose of establishing holders of Less Than Marketable Parcels has been set at close of trade on 15 August, 2016 (Record Date).

As at the Record Date, over 515 of the Company’s approximately 1,864 shareholders held Less Than Marketable Parcels, making up approximately 0.34% of the Company’s fully paid ordinary shares on issue.

To view the full announcement, please click on the button below.

YPB Extends e-Passport Agreement

16th August 2016, ASX Announcement

Brand Protection and Customer Engagement solutions company YPB Group Limited (ASX: YPB) has exercised the option to extend the Memorandum of Cooperation (MOC) with Foilmakers Australia Pty Ltd (FMA) relating to the application of proprietary VariSec technology to e-Passports.

Singed in July 2015, the first year of the agreement has resulted in four order including re-orders for YPB’s VariSec technology, to be applied to newly issued e-Passports for both first world and emerging economies. Continued orders are expected over the next 12 months.

YPB’s VariSec technology has now been applied to three countries’ e-Passport in a marketplace where an estimated 125 million new e-Passports in a marketplace where an estimated 125 million new e-Passports are issued annually.

To view the full announcement, please click on the button below.

Get Picked Up Logistics Aims at East Coast Disruptive Aggregation

11th August 2016, Fully Loaded by Rob McKay

While parcel disruptors have garnered Australian headlines recently, those looking to shake up interstate haulage and metro-distribution are less common.

Enter GPU Logistics, which founder and CEO Daniel Rombouts says is looking to use a technology proven in personal transport to tackle, initially, full trailer load east coast line-haul movements and local Sydney Metro deliveries.

The service will focus on work opportunities for tow operators, singles and B-doubles.

“GPU Logistics is a disruptive transport business using technology to aggregate owner drivers and small fleet operators Australia-wide providing them with access to extra loads, whilst at the same time servicing clients with a fully compliant operator network and the ability to reduce transport costs through the use of technology,” Rombouts says.

To view the full article, please click on the button below.

Omni Market Tide Corporate Presentation August 2016

16th August 2016, ASX Announcement

What We Do 

The Omni Market Tide group produces applications for digital stakeholder engagement. We develop products for enterprise organisations that require professional level, deep engagement applications to help solve complex business problems, and meet regulatory, governance or compliance requirements in their business.

OMT works with both cyber security and physical access providers to extend security and access applications out to mobile devices. Identity and security management are key to our applications.

Why OMT?

  • We have developed application for the leading Australian communication provider
  • We have developed corporate governance applications for one of the big four banks
  • We have developed applications or the investor space
  • We understand enterprise challenges of access to information
  • Physical and identity access via mobile devices
  • We understand enterprise ERP and access control systems

To view the full Presentation, please click on the button below.

Martin Aircraft Company Board and Management Changes

16th August 2016, ASX Announcement

As advised 2 August 2016 Business Update, the Board of Martin Aircraft Company  (MACL or the Company) has been undertaking an in-depth review of the Company’s progress, in particular focusing on how best to both progress the path towards commercialisation of the Series 1 Jetpack whilst effectively managing its costs base. KuangChi Science Limited (KCS), the Company’s cornerstone shareholder, has been consulted as part of this review process.

KCS has investments across a broad array of technology companies. In order to create synergy and lower cost across their investment portfolio KCS has established a Global Community of Innovation (GCI). In essence a group that will explore ways to share services to lower the costs, and leverage technology, across each of the disruptive technology companies within their investment portfolio.

Peter Coker, CEO and Managing Director of MACL, will be stepping down from his role and taking up a newly created role with KCS as their Vice President Global Community of Innovators Business Unit (GCI). James West, currently CFO, has appointed to CEO of MACL.

To view the full announcement, please click on the button below.

Long Pipes Semi Finalist in the Australian Technology Competition

15th August 2016

Long Pipes has developed, demonstrated and installed the Fluid Highway™ the “World’s first” continuous composite pipe made in the field without a joint for 1km or 1,000kms. It is the lowest cost, lightest, strongest, lowest CO2, lowest environmental impact, lowest labour and fastest to install fibre composite pipe globally.  The Fluid Highway ™ is unique it is tough, strong, flexible, designed to withstand extreme corrosion, erosion, temperature variations and pressures up to 130 Bar so far.

Long Pipes is now a semi-finalist in the Australian Technology Competition that will be awarded at the Darling Harbour Maritime Museum on the 2nd of November.

Australian Technology Competition

  • 38 of Australia’s leading technology companies short listed into the Australian Technologies Competition (ATC) Business Accelerator
  • Exceptional quality of entrants taking world leading innovation to global markets
  • Industry leading innovators in the sectors of energy, manufacturing, food & agritech, mining, medtech & pharma, cyber security and smart cities

The Australian Technologies Competition (ATC) has today shortlisted thirty-eight of Australia’s most exciting technology companies for the ATC16 Business Accelerator. These Semi Finalists are industry leading innovators with the capability to become game-changers across the sectors of energy, manufacturing, food & agritech, mining, medical technologies, cyber security and smart cities.

The judging panel features the country’s leading experts in commercialisation, finance, intellectual property and technology development from companies such as Deloitte, Bird&Bird and FB Rice. With a focus on building global success stories, the judges are looking for not only the best technologies but also the best managers and the best business plans.

This year’s 146 entries have jointly spent $190 million to date developing their technologies and have over 600 employees. Whilst many of the Semi Finalists are already selling solutions, they are jointly seeking an additional $80m to bring all the solutions to market.

To download the full article, please click on the link below. 

QBiotics Channel 7 News Feature: Scientists Find Australian Berry to Cure Cancer

15th August 2016, 7 News

A berry found on Australia’s Blushwood tree in the far north is believed to cure many types of cancer. Scientists made the breakthrough with EBC46 making tumours disappear in just 48 hours.

ABOUT QBIOTICS LIMITED

QBiotics Limited is developing a pipeline of promising drugs in the area of cancer and wound healing. Its lead drug, EBC-46, targets solid tumours and is currently in late pre-clinical development in preparation for a Human Clinical Phase I/II trial with the USA’s FDA. EBC-46 is also in late stage development for the veterinary market through the USA’s FDA-CVM.

QBiotics Share Offer is Now Open

We are pleased to inform you that the QBiotics Share Offer is now Open.

The Offer Site on the QBiotics website is now open where you can:

  • Download the replacement Prospectus
  • Apply for shares via the online application process

Go to www.qbiotics.com/prospectus to view the Offer Site or click the Request Offer button blow.

Key Offer Details

Offer Share Price $0.40 per share
Minimum Investment $5,000 / 12,500 shares
Total amount to be raised $10m (up to $2.5m in oversubscriptions)
Offer Opening date 15th Aug 2016
Offer Closing date 9th Sept 2016

 

Investor Roadshow Presentations

We are conducting a series of Investor Roadshow Presentations throughout Australia.  At these presentations, CEO Dr Victoria Gordon will provide an update on recent company activities, and on the development of our anticancer drug EBC-46 and wound healing treatment WH-1.

Below is the Roadshow schedule. These presentations are open to all QBiotics shareholders and interested investors. To attend, please register via the link below.

Date City Time Location Register
Mon 15th Aug Brisbane 6pm to 7.30pm Hilton Brisbane, 190 Elizabeth St, Brisbane CLICK HERE to register for this event
Tues 16th Aug Sydney 6pm to 7.30pm Hilton Sydney, 488 George St, Sydney CLICK HERE to register for this event
Wed 17th Aug Melbourne 6pm to 7.30pm InterContinental Hotel, 495 Collins Street, Melbourne, CLICK HERE to register for this event
Mon 22nd Aug Cairns 6pm to 7.30pm Hilton Cairns, 34 Esplanade, Cairns CLICK HERE to register for this event
Tues 23rd Aug Adelaide 6pm to 7.30pm Hilton Adelaide, 233 Victoria Square, Adelaide CLICK HERE to register for this event

Exclusive Story On Channel 7 News 

Channel 7 News will be airing an exclusive story on QBiotics about the progress of the Human Trials for EBC-46. This will air on the 6pm News tonight (Mon 15th Aug). Please tune in to watch this story.

If you miss the story, you will be able to view it on their website https://au.news.yahoo.com/ fter it has aired.

 

MedAdvisor Signs MoU with Glaucoma Australia Partnership to Assist 300,000 Australians

15th August 2016, ASX Announcement

Highlights

  • MedAdvisor has signed a Memorandum of Understanding with Glaucoma Australia, the leading not-for-profit patient support organisation for people living with glaucoma
  • Glaucoma Australia will become a MedAdvisor Health Association Partner and promote the MedAdvisor platform to more than 300,000 Australians estimated to have glaucoma
  • Builds on MedAdvisor’s growing Health Partner network, providing strong third party validation and support from recognised health association bodies

MedAdvisor Limited (ASX: MDR, the Company), Australia’s leading digital medication adherence company, is pleased to announce that it has signed a Memorandum of Understanding (MoU) with Glaucoma Australia Inc, to help improve medication adherence in patients living with glaucoma.

Glaucoma Australia is the peak not-for-profit patient support organisation for people living with Glaucoma in Australia.

To view the full announcement, please click on the button below.

BPS Makes Transformative Acquisition of Entertainment Publications & Investor Presentation

12th August 2016, ASX Announcement

Highlights:

  • BPS to acquire Entertainment Publications Australia and New Zealand, a leading business -to-consumer (B2C) deals platform which produces the Entertainment Book and the Entertainment Digital Membership
  • Acquisition set to boost BPS’ growth profile with FY17E pro forma revenue growth of 118% and FY17E pro forma EBITDA growth of 49%. Significant future growth potential with the combined BPS group benefiting from a network of 36,000 SMEs, 18,000 NFPs and 550,000 paying customers (“Members”)
  • BPS successfully completes institutional placement, raising $27.5 million to fund the Entertainment acquisition and to provide growth / working capital
  • Institutional placement was significantly oversubscribed with strong demand received from institutional and sophisticated investors
  • All eligible BPS shareholders invited to participate in a non-underwritten Share Purchase Price Plan at the same price as the placement ($0.94)

Leading channel enablement and payments platform provider BPS Technology Limited (“BPS”, “BPS Technology” or “the Company”) is pleased to announce the successful completion of its underwritten $27.5 million institutional placement.

To view the full announcement, please click on the button below.

To view the Investor Presentation, please click on the button below.

Revolutionary 4Dx Locks Major Deal with Top US Hospital

11th August 2016, Australian Anthill Bu Gerald Ainomugisha

Australian medtech start-up, 4Dx is a step closer to the integration of its visionary and breakthrough technology into everyday healthcare through its latest hardware sale to leading U.S. hospital, Cedars-Sinai Medical Center, a California nonprofit public benefit corporation.

Cedars-Sinai has received a grant award of US $600,000 from the United States National Institutes of Health for the purchase of 4Dx’s new preclinical lung scanner, making Cedars-Sinai the first institution scheduled to purchase this advanced instrument, which can help detect lung diseases in their early stages.

The new scanner addresses a dilemma of current antiquated technologies in measuring the impact of cystic fibrosis, asthma, COPD, emphysema and other disorders on the lung.

To view the full article, please click on the button below.

Bill Gates Backs Aussie Biotech Start-Up Atomo Diagnostics

11th August 2016, Sydney Morning Herald By Brian Robins

In a rare public display of support for Australian technology, a large US investment fund backed by Microsoft founder Bill Gates has taken a stake in a local biotech start-up.

Launched in 2010 and based in a converted toolshop in Leichhardt, in Sydney’s inner west, Atomo Diagnostics has developed a testing platform which is making inroads into the industry globally. Winning the backing of the Gates-backed fund sends a strong message to biotechs worldwide, Atomo Diagnostics founder John Kelly said.

The fund raising has reduced the stakes of Atomo’s two main holders – Kelly and Sydney businessman Lang Walker – to below 30 per cent each, with both ending up with a ”smaller share of a bigger pie”, Mr Kelly, who is also the chief executive, said.

“It sends a very strong message to the global market,” Mr Kelly said of the Gates-backed fund’s decision to support his company. “Atomo is one of the few groups it has invested in directly.”

To view the full article, please click on the button below.

Folkestone Maxim A-REIT Securities Fund July 2016 Monthly Report

Monthly Report
July 2016
Over the 12 month period ended 31 July 2016, the Fund returned +26.25% (after fees, before tax), outperforming the Benchmark return of +24.23% by +2.02%.
The July 2016 Monthly Report provides a snapshot of the Fund and the A-REIT sector’s performance.

Atchinson Consultants Reconfirms Recommended Rating
August 2016
Atchison Consultants has reconfirmed its Recommended rating in its annual review of the Folkestone Maxim A-REIT Securities Fund.
Key strengths identified by Atchison Consultants included:

  • Experienced investment team with successful track record of managing
    A-REIT Funds.
  • A strong qualitative approach to investing with a distinct focus on management capability and behaviours.
  • Sustainable long term performance has continued in the past twelve months reflecting adherence to their investment philosophy.
  • High profile provides quality access at Board and management level within investable universe.

The Folkestone Maxim A-REIT Securities Fund is a high conviction, actively managed fund, that gives investors exposure to a mix of quality listed A-REITs that own assets across the retail, residential, commercial, industrial and real estate related social infrastructure sectors.

  • Investment Expertise
  • Exposure to Listed Real Estate
  • High Conviction, Active Strategy
  • Daily Liquidity
  • Quarterly Distributions
  • Strategic Capacity Limit

BioDiem Complete Successful Entitlement Offer

9th August 2016, BioDiem

BioDiem advises that it has now successfully completed the issue and allotment of entitlement and shortfall convertible preference shares under the shortfall facility of its recent Non-Renounceable pro-rata Entitlement Offer.

Funds will be used to progress the next phase of commercialization of BioDiem’s influenza vaccine (LAIV) licensing business; and its antimicrobial, BDM-I, in development for the treatment of infectious diseases through BioDiem’s subsidiary, Opal Biosciences Limited (“Opal Biosciences”).

ABOUT BIODIEM 

With rising concern about viral infections, “superbugs” and antibiotic resistance, BioDiem is well-positioned with its focus on commercialisation of infectious disease therapies and vaccines. An established ‘flu vaccine licencing business is drawing revenue from commercial partners in India and China. Nasovac-S™ is marketed in India and has recently received WHO prequalification which allows export to new markets.

New anti-infectives are needed due to increasing resistance to existing antibiotics, more difficult-to-treat infections, and paucity new treatments. BioDiem’s subsidiary, Opal Biosciences Ltd is an innovative player in infectious disease treatment, targeting human infection – a high growth, commercially attractive market segment.

To view the full announcement, please click on the button below.

Altech Chemicals Appoint Due Diligence Consultants

10th August 2016, ASX Announcement

Highlights:

  • Altech and KfW IPEX-Bank appoint lenders due diligence consultants
  • Technical, market and legal due diligence
  • Reputable international audit firm to provide “expert opinion” also mandated
  • Due diligence initiation meeting held in Stuttgart, Germany
  • Due diligence site visits at Meckering and Johor conducted last week

Altech Chemicals Limited (Altech/the Company) (ASX: ATC) is pleased to provide an important update on the progress of financing for its proposed high purity alumina (HPA) project.

Following the announcement 3 August 2016, of a positive pre-assessment by the German Government inter-ministerial committee (IMC) and Euler Hermes Aktiengesellschaft (Euler Hermes) of Altech’s export credit project finance application (refer ASX Announcement dated 3 August 2016 for details), due diligence consultants have now been appointed.

To view the full announcement, please click on the button below.

Powerhouse Ventures to Raise $21 Million From ASX Listing

3rd August 2016, Computerworld NZ, By Stuart Corner

Christchurch-based technology commercialisation company, Powerhouse Ventures, has lodged a prospectus with the Australian Stock Exchange for an IPO to raise up to $A20 million ($21m), after earlier flagging its intention to list on the NZX.

Chairman Kerry McDonald said the company would look to expand its operations into Australia. “We propose to enter the Australian market at a time when governments are determined to ensure university research funding generates commercial outcomes. Powerhouse intends to be a central part of this environment with its excellent university engagement model, business building expertise, capital and networks.”

McDonald said the offer would give investors the opportunity to invest in a business that will “identify and transform intellectual property from New Zealand and Australian universities into globally successful businesses.”

To view the full article, please click on the button below.

Folkestone Education Trust Results FY16: Profit of $106.8 million, an Increase of 20.5%

Folkestone Investment Management Limited as Responsible Entity of the Folkestone Education Trust (“FET” or the “Trust”) provides the results of the Trust for the year ended 30 June 2016.

Key Highlights
  • Statutory profit of $106.8 million, an increase of 20.5% from $88.6 million in the previous corresponding period (“pcp”)
  • Distributable income of $34.5 million, an increase of 16.2% on pcp
  • Distribution of 13.4 cents per unit (“cpu”), an increase of 4.7% on pcp
  • NTA per unit of $2.14, an increase of 17.6% from 30 June 2015
  • Total Unitholders’ return for the year to 30 June 2016 of 34.8%
  • New debt facilities were entered into with ANZ and HSBC resulting in the Trust having an average debt maturity of 4 years
  • Development pipeline of 18 centres with a total value of $103.4 million. Six development sites commenced operations during the year with a completion value of $26.3 million

An investor teleconference will be held at 2.30pm AEST today.  To register for the teleconference, please click on the link below.

For further information on FET’s results, please click on the links below.

US Residential Fund Patriot’s Pointe Syndication Live on Crowdfunding Platform

9th August 2016, ASX Announcement

US Residential Fund (ASX: USR “the Fund”) is pleased to announce that its first multifamily residential property syndication is now open to accredited investors through the online syndication platform CrowdStreet.

The property being syndicated, Patriot’s Pointe, is an A grade, 240-unit residential apartment complex set on 25 acres in North Carolina and purchased with attractive 30+ year fixed debt at 3.7% p.a. in place. Through the sydnication, USR is seeking to deliver investors:

Initial yield – 7.2%
Average 5-year yield – 8.1%
Total 5-year  IRR – 15-17%

The CrowdStreet platform’s main focus is investors that are US citizens. However, the Patriot’s Point syndication includes a structure that provides non-US investors the option of participating without having to file a tax return in the US.

To view the full announcement, please click on the button below.

Leaf Resources Investor Presentation August 2016

8th August 2016, ASX Announcement

Company Overview: Leaf Resource sis a green chemical company that uses plant waste/biomass to create industrial chemicals to replace petrochemicals in manufacturing.

  • Leaf’s Glycell™ process converts plant biomass into industrial sugars (a key component used to create green/sustainable chemicals)
  • Large cost advantage over other processes that create industrial sugars
  • Glycell™ is well-suited for a low-carbon world as it is sustainable, carbon friendly and cuts carbon emissions

The Problem: The world is actively shifting from petroleum based products

  • The high cost and environmental impact of burning finite resources has seen industry moving from the ‘black economy’ to the green economy.
  • Manufacturers are moving away from petrochem due to environmental concerns.
  • However, fossil-based petrochemicals are indispensable in our current society.

To view the full Presentation, please click on the button below.

Folkestone Seniors Living Fund No.1 Now Open for Investment

FSLF is well positioned for growth from the acquisition of Watermark Castle Cove, an award winning retirement living community on Sydney’s lower north shore, that is to be expanded (Initial Asset) and to acquire other high quality retirement living communities which may comprise both existing facilities and/or development opportunities in Sydney. Castle Cove is located approximately 12 kilometres north of the Sydney CBD.

The key investment highlights of the Fund include:

Exposure to Key Sector
- seniors living is a key and growing part of the economy
- ageing population is focusing on quality retirement accommodation

Strong Demographics
underpinned by ageing population
- positive demand for seniors living products

Attractive Returns

- targeting 15% IRR (pre-tax, post fees) over life of Fund

Experienced Partners
- partnering with key strategic developer/operators focusing on high quality, facilities with an excellent service culture

Quality Assets

- relatively new retirement living communities located in Sydney

Off Market Opportunity
- initial asset has been acquired off market via Folkestone’s network

The Final Close of the Offer will be the earlier of 9 September 2016 and the date when the total of the capital has been raised. The Fund has an expected term of 7.0 years.

AsiaPhos Reports Net Attributable Profit of S$0.4 million in 2Q2016

AsiaPhos Limited (“AsiaPhos” or the “Company”, and together with its subsidiaries, the “Group”), a Singapore-headquartered mineral resources company focused on exploring and mining phosphate with a vertically-integrated business model, reported its unaudited financial results for the second quarter ended 30 June 2016 (“2Q2016”).

In the quarter under review, the Group’s net attributable profit was S$0.4 million, compared to S$0.5 million in the corresponding period last year (“2Q2015”). Excluding non-cash charges of mainly depreciation and amortisation, the Group’s operating profit before working capital changes improved from S$1.2 million in 2Q2015 to S$2.0 million in 2Q2016.

Revenue for the Group was S$9.6 million in 2Q2016, against S$12.0 million in 2Q2015. The lower revenue was mainly due to the upstream operations which saw revenue decreasing from S$6.5 million in 2Q2015 to S$3.6 million in 2Q2016, as the Group retained the higher quality phosphate rocks for its in-house P4 production, and sold only the lower quality rocks AsiaPhos Limited: 2Q2016 Results Press Release which fetched lower average selling prices. In addition, the quantity of rocks sold in 2Q2016 was 57,600 tonnes, compared to 89,100 tonnes in 2Q2015.

On the other hand, revenue from downstream operations rose from S$5.5 million in 2Q2015 to S$6.0 million in 2Q2016, driven by the higher sales of P4 from 1,900 tonnes in 2Q2015 to 2,300 tonnes in 2Q2016.

In its continual efforts to improve prod production efficiency, by securing cheaper electricity costs and carrying out improvements to one of its furnaces, the Group had successfully reduced the production cost of P4 in 2Q2016. This led to an overall improvement in the Group’s gross profit margin to 20% in 2Q2016, from 17% in 2Q2015.

Commenting on the results, Dr Ong Hian Eng (王显荣博士), Chief Executive Officer of AsiaPhos Limited said,

“The mining season had resumed in March this year, and our mining output run-rate is showing a promising growth trend. We were able to achieve an average daily output of about 1,800 tonnes in 2Q2016, which far exceeds the average of 1,400 tonnes in FY2015. This is the direct result of our previous investments in improving our mining infrastructure, and we expect to increase our rock production in FY2016 which should contribute positively to the Group’s cash flows and profits.”

Outlook

For the remainder of the current financial year ending 31 December 2016 (“FY2016”), phosphate rock prices are expected to soften moderately. Meanwhile, in July 2016, the Sichuan Provincial People’s Government (四川省人民政府) announced that, with effect from 1 July 2016, the policy to collect a price adjustment levy and resource compensation fee amounting to RMB14 per tonne of phosphate rock will be abolished. At the same time, the resource tax will be computed based on 8% of the selling price of the phosphate rocks, instead of a fixed RMB15 per tonne of phosphate rock. Based on the current available information, the Group expects that the above changes will lead to a reduction in production cost of the phosphate rocks in the second half of FY2016.

The price outlook for P4 is expected to remain challenging. Though the Group anticipates production cost for P4 to be lower in FY2016 than the previous year, it will continue to monitor the situation and take steps to ensure the economic production and profitability of P4. The Group will continue to diversify revenue contribution from the downstream business segment by exploring the export market for P4 and other downstream phosphate-based chemical products.

Corporate Updates

In July 2016, the Group received the renewed exploration rights for the Fengtai Mine and Mine 2, with the renewed rights being valid till December 2017 and June 2018 respectively.

Earlier this year, the Group had submitted an application to the Sichuan Land Department (“Authority”) to convert the Mine 1 exploration license into a mining license so that the approved annual production scale for Mine 1 can be increased from 50,000 tonnes to potentially 400,000 tonnes. The application is currently pending approval by the Authority.

YPB Protects Retailer Dan Murphy’s Against Theft

5th August 2016, ASX Announcement

Highlights:

  • YPB’s Lexcaps used as anti-theft deterrent across Dan Murphy’s retail outlets
  • Estimated that Dan Murphy’s will use more than 100,00 units per annum

Brand Protection and Customer Engagement solutions company YPB Group Limited [ASX: YPB] today announced that its proprietary anti-theft Lexcaps will be used across Dan Murphy’s stores Australia wide.

YPB’s Lexcaps are reusable security caps that are applied to bottle caps and removed by service staff at the point of sale. A person attempting to steal a bottle with a Lexcap will trigger an alarm at the exit.

In successful trials with the liquor industry and Dan Murphy’s in particular, theft was reduced significantly on YPB protected liquor bottles.

To view the full announcement, please click on the button below.

YuuZoo FY16 Update: Signs Agreement with Etisalat, for Launch of Powerful New E-Commerce Platform Targeting SMEs

YuuZoo together with Etisalat, the largest mobile operator in Africa and the Middle East, will launch a powerful new e-commerce platform targeting the country’s SME market. “SME Arena” (www.smearena.com.ng) which is built and managed by YuuZoo and marketed in Nigeria by Etisalat, helps SMEs to market and sell their products and services. Users of SME Arena can also enjoy the tribal social networks and games offered on the platform.  This agreement has unlocked immediate access for YuuZoo to an additional of 24 million Nigerian subscribers while targeting Nigeria’s entire 180 million population.

ABOUT YUZOO

Listed on the SGX mainboard (SGX: AFC), with access to over 45 million registered users, 700 million TV viewers and 100 million followers in 164 countries, YuuZoo has created a globally unique and profitable new business model in social media.

Social networking, e-commerce and gaming is offered to consumers in a mobile-optimized virtual shopping mall, where they can access hundreds of targeted social networks, shops and entertainment through one single login. The company grows internationally through a profitable franchise model. All networks are localized for each market in language, merchandise and design.

Prescient Therapeutics Granted USPTO Allowances for Two PTX-200 Patents

4th August 2016, ASX Announcement

Clinical-stage oncology company Prescient Therapeutics Limited (ASX:PTX) is pleased that the US Patent and Trademark Office (USPTO) has issued two notices of allowance under the PTX-200 patent families “Effective treatment of tumors and cancer with triciribine and related compounds” and “Compositions including triciribines and taxanes and methods of use thereof“.

The first allowance bears relevance to claims involving the intravenous dosing schedule of novel Akt inhibitor, PTX-200, including a method for identifying and treating patients with tumors in the pancreas, ovary or colon that have highly expressed Akt.

The second allowance has allowed claims bearing particular relevance to PTX’s ongoing breast cancer clinical trial, involving the use of PTX-200 with taxanes.

To view the full announcement, please click on the button below.

DomaCom’s IPO Goes Live 31st August – Offer Closing Soon!

DomaCom lodged its Prospectus with ASIC on the 24th July and is planning to IPO on the ASX on the 31st August. The Offer is currently open and investors can participate for as little as $2,250. Below is an update on the most recent events and media for DomaCom.

ABOUT DOMACOM

DomaCom Ltd is the first and only regulated fractional property platform in the country. Following a 5-year development and launch phase which has seen the company acquire 16 properties and initiate another 37 bookbuilds, DomaCom is taking the next major step in its corporate journey with a listing on the ASX. DomaCom is seeking to raise $10 million in the IPO, with $5 million already underwritten.

 

Altech Positive Pre-Assessment German Export Credit Finance

3rd August 2016, ASX Announcement

Highlights

  • Positive pre-assessment by German inter-ministerial committee
  • Important milestone in the assessment process of Altech’s ECA application
  •  Formal detailed due dilligance of the project to commence

Altech Chemicals Limited (Altech/the Company) (ASX: ATC) is pleased to report that it has been officially advised by Euler Hermes Aktiengesellschaft (Hermes), the German Export Credit Agency (ECA), of a positive pre-assessment by the German Government inter-ministerial committee (IMC) and Hermes, of Altech’s export credit project finance application for cursory review (refer ASX Announcement dated 22 March 2016 for details).

The positive pre-assessment of Altecch’s export credit application is an important milestone in the assessment process of the Company’s high purity alumina (HPA) project and its  ECA application.

To view the full announcement, please click on the button below.